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ABSTRACT 
 
The pharmaceutical industry is suffering from declining R&D productivity 
and  yet  biopharmaceutical  firms  have  been  attracting  increasing  venture 
capital investment. Effective R&D portfolio management can deliver above 
average returns under increasing costs of drug development and the high 
risk of clinical trial failure. This points to the need for advanced decisional 
tools  that  facilitate  decision-making  in  R&D  portfolio  management  by 
efficiently  identifying  optimal  solutions  while  accounting  for  resource 
constraints such as budgets and uncertainties such as attrition rates. This 
thesis presents the development of such tools and their application to typical 
industrial portfolio management scenarios. 
A  drug  development  lifecycle  cost  model  was  designed  to  simulate  the 
clinical and non-clinical activities in the drug development process from the 
pre-clinical stage through to market approval. The model was formulated 
using activity-based object-oriented programming that allows the activity-
specific information to be collected and summarized. The model provides 
the decision-maker with the ability to forecast future cash flows and their 
distribution across clinical trial, manufacturing, and process development 
activities. The evaluation model was applied to case studies to analyse the 
non-clinical  budgets  needed  at  each  phase  of  development  for  process 
development  and  manufacturing  to  ensure  a  market  success  each  year. 
These cost benchmarking case studies focused on distinct product categories, 
namely pharmaceutical, biopharmaceutical, and cell therapy products, under 
different attrition rates.  
A stochastic optimization tool was built that extended the drug development 
lifecycle cost evaluation model and linked it to combinatorial optimization 
algorithms  to  support  biopharmaceutical  portfolio  management  decision-
making.  The  tool  made  use  of  the  Monte  Carlo  simulation  technique  to 
capture the impact of uncertainties inherent in the drug development process. 
Dynamic simulation mechanisms were designed to model the progression of 
activities  and  allocation  of  resources.  A  bespoke  multi-objective  
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evolutionary  algorithm  was  developed  to  locate  optimal  portfolio 
management solutions from a large decision space of possible permutations. 
The  functionality  of  the  tool  was  demonstrated  using  case  studies  with 
various budget and capacity constraints. Analysis of the optimization results 
highlighted the cash flow breakdowns across both activity categories and 
development stages.  
This  work  contributed  to  the  effort  of  providing  quantitative  support  to 
portfolio  management  decision-making  and  illustrated  the  benefits  of 
combining cost evaluation with portfolio optimization to enhance process 
understanding and achieve better performance.  
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LITERATURE REVIEW 
1.1  INTRODUCTION 
The biopharmaceutical R&D activities are highly costly, time consuming 
and technology intensive. Each biopharmaceutical new drug development 
process costs more than $1.2 billion (DiMasi & Grabowski 2007), with the 
development duration between the new drug discovery and market approval 
ranging  from  5  to  10  years  (Werner  2004).  The  development  of  a 
biopharmaceutical  new  drug  consists  of  several  distinct  phases,  which 
require  specific  planning  of  resource  investment.  The  manufacture  of 
biopharmaceuticals  is  one  of  the  most  highly  regulated  and  complex 
processes that requires intensive control and significant capital investment 
on  the  design,  planning  and  construction  of  the  facility  (Goldstein  & 
Thomas 2004). Drug developers are also facing diminishing returns from 
R&D  investment  as  the  number  of  new  products  approved  by  FDA  per 
billion dollar on R&D spending has halved every 9 years (Scannell et al. 
2012). To maintain competitive advantages, biopharmaceutical developers 
must sustain intensive innovation either from in-house pipeline development 
or by acquiring outside product candidates. This brings up the need of a 
comprehensive  decision-support  tool  for  drug  developers  that  not  only 
focuses  on  finding  the  optimal  portfolio  management  solutions,  but  also 
provides guidance on budget and capacity planning. Therefore, in this thesis, 
computational  decisional  tools  were  developed  to  optimize  the 
biopharmaceutical portfolio decision-making under resource constraints and 
to characterize the costs associated with various development activities. 
In this chapter, the background and scope of this work are introduced by 
reviewing  published  literature  on  the  drug  development  process, 
biopharmaceutical portfolio management decision-making, and modeling & 
optimization  approaches.  The  remainder  of  this  chapter  is  structured  as 
follows.  Section  1.2  introduces  the  biopharmaceutical  drug  development Chapter 1  
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process,  including  a  brief  overview  of  the  activities  and  stages  that 
constitute the drug development lifecycle. Section 1.3 reviews some of the 
key topics that influence biopharmaceutical portfolio management decision-
making. Important computational modeling and optimization techniques are 
discussed  in  Section  1.4  as  well  as  their  implementations  in 
biopharmaceutical industry. Finally, the aim and organization of this thesis 
are presented in Section 1.5.  
1.2  BIOPHARMACEUTICAL DRUG DEVELOPMENT PROCESS 
Biopharmaceuticals  have  been  defined  as  “protein  or  nucleic  acid  based 
pharmaceutical  substances  used  for  therapeutic  or  in  vivo  diagnostic 
purposes, which are produced by means other than direct extraction from 
natural  biological  sources”  (Walsh  2006).  The  biopharmaceutical  drug 
development process consists of a number of different stages. In the pre-
clinical trial phase, the new drug candidate is subject to a range of tests both 
in vitro and in animals in order to characterize the drug in terms of its likely 
safety and effectiveness in treating its target disease. Upon completion of 
the pre-clinical trial, the drug developer applies to regulatory authorities (e.g. 
the FDA in USA) for approval to commence clinical trials in humans, which 
are required to prove that the drug is safe and effective when administered 
to patients. The clinical trial work commences once the toxicity of the drug 
has been characterized, and the company normally patents the drug in order 
to ensure a period of monopoly in the market.  
Conventionally, there are three major phases of human clinical trials before 
a drug can be granted market approval: Phase I mainly focuses on the safety 
aspect of the product and the size of the trial is relatively small compared to 
other clinical trial phases. In Phase II, the efficacy of the drug is put to test 
where double-blinded studies are normally adopted to ensure objectivity. 
This  is  also  the  phase  with  the  highest  probability  of  failure  for 
biopharmaceuticals.  Large  numbers  of  patients  are  required  in  Phase  III 
trials  as  the  regulatory  authorities  expect  more  accurate  estimates  of  the 
efficacy  and  dosage  of  the  drug  in  a  larger  population  before  granting Chapter 1  
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permission for marketing. This is also the most expensive and lengthy phase 
for development of biopharmaceuticals. Preparations for market launch are 
also triggered at this phase, since the manufacturing process is normally 
locked from this stage onwards.  
At the regulatory review stage, the drug developer is required to gather all 
pre-clinical and clinical data, along with characterization of the production 
process,  and  submit  them  to  the  regulatory  authorities  for  approval  of 
market  entry.  The  go-ahead  from  regulatory  authorities  after  the  review 
stage  enables  the  drug  developer  to  legally  manufacture  and  market  the 
product for profit. But regulatory involvement does not end at this point; 
post-marketing  surveillance,  also  known  as  Phase  IV  clinical  trial,  is 
generally  undertaken,  in  which  the  company  is  obliged  to  report  any 
subsequent  drug-induced  side  effects  or  adverse  reactions.  Regulatory 
authorities  also  inspect  the  manufacturing  facilities  every  two  years  to 
ensure  that  satisfactory  manufacturing  standards  are  complied  (Walsh  & 
Murphy 1999). 
1.2.1  Development time, cost, and success rate 
Biopharmaceutical drug development is a lengthy and expensive procedure. 
DiMasi claimed that the estimated average out-of-pocket clinical period cost 
per approved new drug is $361 million, and the average out-of-pocket pre-
clinical  period  cost  per  approved  new  drug  is  $198  million  (DiMasi  & 
Grabowski 2007). These results are concluded by evaluating project-level 
aggregated annual expenditure data from biotech firms, and are primarily 
targeted  on  therapeutic  recombinant  proteins  and  monoclonal  antibodies 
(mAb). The risks associated with the new drug development process are 
incorporated to derive these figures.  
There are four main factors that drives the drug R&D costs: 1) the out-of-
pocket  costs  for  development  phases,  2)  the  success  rates,  3)  the 
development times, and 4) the cost of capital (Jorge Mestre-Ferrandiz 2012). 
Several  published  empirical  studies  have  summarized  the  out-of-pocket 
costs  of  different  clinical  phases  from  databases  of  pharmaceutical 
companies. Table 1.1 presents the predominate figures in pharmaceutical Chapter 1  
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and  biopharmaceutical  product  development  cost  estimations.  There  are 
significant variations in the out-of-pocket phase costs of almost all phases of 
drug development process among the studies. For clinical trial Phase I to III, 
Bogdan  and  Villiger’s  (2010)  estimations  of  the  out-of-pocket  costs  are 
considerably lower than other sources. 
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In 2003, DiMasi and co-workers estimated that the total development cost 
per drug was $802 million (DiMasi et al. 2003). This was considered to be 
lower than the real situation by Adams and Brantner, who estimated that the 
average capitalized development cost per new drug is $1 billion (Adams & 
Brantner  2006),  using  the  publicly  accessible  database  Pharmaprojects. 
DiMasi responded with new figures that raised the estimation of capitalized 
cost to $1.2 billion for biopharmaceuticals (DiMasi & Grabowski 2007). 
Together,  these  studies  show  that  the  cost  of  innovation  in 
biopharmaceutical industry is rising.  
Adams and Brantner also estimated the durations of clinical trial phases for 
drugs being developed by different groups of firms by market position. The 
average durations of clinical trials for three of the highly ranked groups of 
pharmaceutical firms are presented in Table 1.2. 
Table 1.2 Average phase time for investigational compounds by firm (Adams 
& Brantner 2006). 
  Phase duration (months) 
Development 
stage 
Top 10 by 2001 
income 
Top 20 by Fortune 
rank 
Top 10 by drug 
count 
Phase I  17  21  18 
Phase II  19  23  27 
Phase III  25  29  28 
 
The  success  rates  of  monoclonal  antibody  therapeutics  are  presented  in 
Table 1.3. These data were collected by the Tufts Centre in a study of drug 
development,  which  included  355  mAb  therapeutic  products  in  clinical 
studies sponsored by more than 100 commercial firms worldwide (Reichert 
2001). According to the consolidated results, the type of the mAb also has 
an  impact  on  its  clinical  trial  success  rates.  As  presented  Table  1.3,  the 
average success rate of mAb therapeutics is around 20%.  
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Table  1.3  Success  rates  for  mAb  therapeutics  by  type  and  application 
(Reichert 2001). 
mAb type and application  Success rate on approval (%) 
Oncological chimeric mAb  18 
Oncological humanized mAb  24 
Immunological chimeric mAb  22 
Immunological humanized mAb  19 
 
The  success  rates  of  investigational  biopharmaceuticals  provide  drug 
developers  with  a  picture  of  the  probable  outcome  of  their  development 
projects. However, from a development process modeling point of view, the 
phase transition probabilities more accurately characterize the likelihood of 
a product reaching certain development stages. Evaluation of expected and 
capitalized  cost  for  developing  novel  biopharmaceuticals  is  largely 
dependent on the phase transition probabilities.  
Several studies have been published on the phase transition probabilities for 
pharmaceuticals  and  biopharmaceuticals  in  various  therapeutic  areas, 
selected  results  from  which  are  presented  in  Table  1.4.  In  the  area  of 
monoclonal  antibodies,  a  study  conducted  by  Reichert  summarized  the 
phase transition probabilities for mAb in clinical trials from 1980 to 2000 
(Reichert 2001); those results were further updated when a follow-on study 
focusing on mAb therapeutics from 1980 to 2006 was conducted in 2008 
(Reichert 2008). Table 1.4 shows the data on humanized mAb from these 
studies. For biopharmaceuticals and pharmaceuticals in general, the phase 
transition probabilities were summarized in cost estimation studies, in which 
the  expected  capitalized  cost  for  developing  one  successful  product  was 
estimated based on the number of products required in each phase (DiMasi 
& Grabowski 2007). Additional data came from a study on a database of 
more  than  1055  pharmaceutical  drugs,  summarizing  the  probabilities  of 
entering a given phase, which can also be translated into phase transition 
probabilities  displayed  in  Table  1.4  (Adams  &  Brantner  2006).  The Chapter 1  
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probabilities of phase transition from pre-clinical trial to Phase I trial for 
pharmaceuticals  was  estimated  in  a  study  focusing  on  improving  R&D 
productivity for the pharmaceutical industry (Paul et al. 2010). Finally, the 
latest study on clinical success rates of drugs in various therapeutic areas 
summarized  the  phase  transition  probabilities  for  new  molecular  entities 
(NMEs)  and  biologics  by  FDA  classification.  The  phase  transition 
probabilities  of  large  molecules  and  mAbs  from  Biomedtracker  product 
categories  were  also  presented  (Hay  et  al.  2014).  These  results  provide 
important source of information for further analyses.   
   Chapter 1  
  24 
T
a
b
l
e
 
4
 
P
h
a
s
e
 
t
r
a
n
s
i
t
i
o
n
 
p
r
o
b
a
b
i
l
i
t
i
e
s
 
o
f
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
a
n
d
 
b
i
o
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
s
 
S
o
u
r
c
e
 
P
r
o
d
u
c
t
 
c
a
t
e
g
o
r
y
 
P
r
e
-
c
l
i
n
i
c
a
l
 
t
o
 
P
h
a
s
e
 
I
 
(
%
)
 
P
h
a
s
e
 
I
 
t
o
 
I
I
 
(
%
)
 
P
h
a
s
e
 
I
I
 
t
o
 
I
I
I
 
(
%
)
 
P
h
a
s
e
 
I
I
I
 
t
o
 
r
e
v
i
e
w
 
(
%
)
 
R
e
v
i
e
w
 
t
o
 
m
a
r
k
e
t
 
(
%
)
 
R
e
i
c
h
e
r
t
 
2
0
0
1
 
H
u
m
a
n
i
z
e
d
 
m
A
b
s
 
N
/
A
 
8
4
 
7
2
 
7
5
 
1
0
0
 
R
e
i
c
h
e
r
t
 
2
0
0
8
 
H
u
m
a
n
i
z
e
d
 
m
A
b
s
 
N
/
A
 
8
3
 
4
4
 
8
2
 
(
P
h
a
s
e
 
I
I
I
 
t
o
 
a
p
p
r
o
v
a
l
)
 
D
i
M
a
s
i
 
&
 
G
r
a
b
o
w
s
k
i
 
2
0
0
7
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
 
N
/
A
 
7
1
 
4
4
.
2
 
6
8
.
5
 
(
P
h
a
s
e
 
I
I
I
 
t
o
 
a
p
p
r
o
v
a
l
)
 
B
i
o
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
N
/
A
 
8
3
.
7
 
5
6
.
3
 
6
4
.
2
 
(
P
h
a
s
e
 
I
I
I
 
t
o
 
a
p
p
r
o
v
a
l
)
 
P
a
u
l
 
e
t
 
a
l
.
 
2
0
1
0
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
 
6
9
 
5
4
 
3
4
 
7
0
 
9
1
 
A
d
a
m
s
 
&
 
B
r
a
n
t
n
e
r
 
2
0
0
6
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
 
N
/
A
 
6
1
 
7
2
 
4
3
 
(
P
h
a
s
e
 
I
I
I
 
t
o
 
a
p
p
r
o
v
a
l
)
 
H
a
y
 
e
t
 
a
l
.
 
2
0
1
4
 
N
M
E
s
 
N
/
A
 
6
4
.
2
 
2
8
.
6
 
5
3
.
2
 
7
6
.
5
 
B
i
o
l
o
g
i
c
s
 
N
/
A
 
6
8
.
4
 
3
7
.
9
 
6
3
.
2
 
8
8
.
8
 
L
a
r
g
e
 
m
o
l
e
c
u
l
e
s
 
N
/
A
 
6
5
.
8
 
3
7
.
7
 
6
0
.
1
 
8
8
.
6
 
m
A
b
s
 
N
/
A
 
7
0
.
1
 
3
8
.
1
 
6
0
.
7
 
8
6
.
8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
a
b
l
e
 
1
.
4
 
P
h
a
s
e
 
t
r
a
n
s
i
t
i
o
n
 
p
r
o
b
a
b
i
l
i
t
i
e
s
 
o
f
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
a
n
d
 
b
i
o
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
s
 
.
 
 Chapter 1  
  25 
1.2.2  Manufacturing biopharmaceuticals 
Biopharmaceutical manufacturing is one of the most highly regulated and 
complex processes that requires intensive control and capital investment for 
design,  planning  and  construction  of  the  facility  (Goldstein  &  Thomas 
2004).  The  production  process  can  be  divided  into  upstream  and 
downstream processing. Upstream processing refers to the generation of the 
product through fermentation or cell culture processes, while downstream 
processing refers to the purification of the product from the fermentation 
broth  and  the  formulation  of  the  final  product.  The  bulk  of 
biopharmaceuticals currently on the market are mainly produced by genetic 
engineering  using  various  recombinant  expression  systems.  Although  a 
wide range of potential protein production systems are available, most of the 
recombinant proteins that have gained market approval so far are produced 
either  in  E.coli  or  in  mammalian  cell  lines.  Using  E.coli  as  a  source  of 
biopharmaceutical  production  has  certain  advantages  such  as  the  high 
expression rate and rapid growth rate. The vast bulk of proteins synthesized 
by E.coli are intracellular; therefore additional primary processing steps are 
required to break cells, and purification processes are required to separate 
target proteins from other impurities. On the other hand, mammalian cell 
lines as a source of biopharmaceutical production are capable of producing 
special  protein  products  that  require  post-translational  modifications. 
However, compared to E.coli, mammalian cell lines require more complex 
nutritional  feeding  and  the  growth  is  relatively  slow.  Additionally, 
mammalian cells are often considered more fragile when exposed to shear 
forces. The disadvantages of both expression systems for biopharmaceutical 
production  increase  the  complexity  of  the  manufacturing  process  and 
production cost.  
The number of patients needed for a clinical study dictates the minimum 
material requirement. Table 1.5 presents details of the typical dosage and 
patient numbers in clinical trials and in market (Simaria et al. 2012).  Chapter 1  
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Table 1.5 Typical dosage and patient number for clinical trials and market 
Material requirement level  Low  Medium  High 
Dosage per body weight (mg/kg)  1  7  15 
Dosage (mg), 150kg BW  150  1050  2250 
No. of doses per patient per year  6  26  52 
No. of patients in Phase I  20  40  80 
No. of patients in Phase II  100  200  300 
No. of patients in Phase III  1000  2000  3000 
No. of patients in market  10000  100000  1000000 
 
According to the range of dosage and patient numbers provided in Table 1.5, 
the possible range of batch numbers required for each phase for the three 
material requirement levels can be calculated (see Table 1.6). An illustration 
of the kilogram demands and batch numbers is shown in Table 1.6 for an 
assumed titre of 3g/L for mAb production for small and large scale and 
fermenter space efficiency of 70% (Chon & Zarbis-Papastoitsis 2011). . One 
contingency batch was added for production of each clinical trial stage, as 
there is risk of contamination (Lim et al. 2005). 
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Table 1.6 Material and batch required for clinical trial production.  
Clinical trial material requirement level  Low  Medium  High 
Phase I material (g) per year  18  1092  9360 
Phase II material (g) per year  90  5460  35100 
Phase III material (g) per year  900  54600  351000 
Phase I batch per year (100L)  2  7  46 
Phase II batch per year (500L)  2  7  35 
Phase III batch per year (5000L)  2  7  35 
Note: Titre is assumed at 3g/L level and working volume 70%. One contingency 
batch added for each clinical trial. 
 
1.3  BIOPHARMACEUTICAL PORTFOLIO MANAGEMENT DECISION-
MAKING 
Apart from the characteristics of biopharmaceutical products overviewed in 
the  previous  section,  portfolio  management  decision-making  at  an 
organizational level is also driven by parameters both inside and outside the 
boundary  of  organizations.  In  this  section,  the  single  decision-making 
criterion, net present value (NPV) is introduced, along with a number of 
factors  that  influence  biopharmaceutical  portfolio  management  decision-
making.  
Table  1.7  lists  the  key  factors  that  influence  biopharmaceutical  portfolio 
management decision-making. For the decision-makers, these factors can be 
the resource characteristics of the firm, such as the capacity for production 
of  biopharmaceuticals  at  commercial  scale  and  the  availability  of  large 
amounts of R&D budget, or the environment that changes the industrial 
product development landscape and market potential. The factors within the 
boundaries of firms can be altered in the decision-making process in order 
to achieve better outcomes.  The factors outside the boundaries of firms can 
only be treated as given, or inputs to the decision-making process.  
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Table 1.7 Factors that drive the portfolio management decision-making 
Factor  Implications to decision-making 
Product market 
potential 
This factor affects the amount of cash inflow once the 
product is approved for marketing. It has no cash flow 
implication if the product fails. Therefore the more likely the 
product goes to market, the more influential this factor 
becomes.  
Capacity 
bottleneck 
This factor could be potentially devastating as it adversely 
influences the capability of drug development firms realizing 
the full value of product. Portfolio management decisions 
should comply with the capacity planning of the firm. 
R&D budget 
Increasing the R&D expense loosens the restriction on 
maximum number of projects the drug development firms 
can take. However, the extra fund could potentially alter the 
cost-of-capital for the firm, depends on the source of the fund 
and existing capital structure of the firm.  
Industrial 
landscape on new 
product 
development 
Key considerations when the environment of new product 
development changes: 
Does it introduce more competition? 
Is there any opportunity to add value by acquiring outside 
products or out-licensing in-house product? 
 
1.3.1  Net present value 
Net  present  value  (NPV)  has  been  widely  accepted  as  the  quantitative 
indicator of the value brought by the investment with implications to future 
cash flows. The NPV rule for investment decision-making suggests using 
NPV as the sole criterion and accepting the strategy that maximizes the 
portfolio NPV. Compared to other investment decision-making criteria, the 
NPV rule has the following advantages: 
1.  It can be universally applied to almost all industrial decision-making 
optimization scenarios that concern the impact on future cash flows.  Chapter 1  
  29 
2.  It takes into account the length of investment projects by using the 
discounted cash flow method. 
3.  It covers the potential benefit of investment even after the cost of 
investment  is  fully  recovered.  Decision-making  criteria  based  on 
payback period only focuses on the length it takes the project to 
recover  the  cost,  but  overlook  the  cash  flows  generated  by  the 
project afterwards. Using the NPV rule, decision alternatives that 
lead  to  different  cash  flow  projections  after  the  cost  is  fully 
recovered can be distinguished.  
4.  Compared to the internal rate of return (IRR) rule, the NPV rule has 
the flexibility of covering the investment projects that may generate 
mixed positive and negative cash flows. With these projects, a single 
IRR cannot be used to describe the returns of investment.  
However, when applying the NPV rule for investment decision-making, the 
users  do  need  to  specify  the  appropriate  discount  rate,  which  could  be 
difficult  to  obtain.  The  concept  of  discount  rate  is  originated  from 
opportunity cost, which requires that the return of investment should be at 
least equal to the investment in financial markets that bears the same risk. 
Failing  this,  the  investment  decision  will  lead  to  negative  NPV.  For 
decision-making  at  corporate  level,  the  firm’s  weighted  average  cost  of 
capital is often used as discount rate. 
Empirical  studies  on  cost-of-capital  of  pharmaceutical  and 
biopharmaceutical  industry  have  shown  that  using  capital  asset  pricing 
model  (CAPM),  the  real  cost-of-capital  ranges  from  8.6%  to  9.5%  for 
pharmaceutical firms, and 8.6% to 10.3% for biotechnology firms. Using 
Fama and French model (F-F), the cost-of-capital for pharmaceutical firms 
ranges from 8% to 9.5%, and for biotechnology firms it ranges from 8.2% to 
10.5%, depending on the size of the firm (Harrington 2012). 
1.3.2  Construction of industrial manufacturing facilities 
For new biopharmaceutical developers who do not suffer from harsh budget 
constraints,  building  an  in-house  manufacturing  facility  for  new  product 
manufacturing  is  considered  more  profitable  than  using  contract Chapter 1  
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manufacturing  organizations  (CMO)  in  the  long  run  (Demeter  2003).  A 
previous  process  simulation  and  optimization  model  also  suggests  that 
building an in-house facility tends to result in more profit in the future than 
using CMOs (George et al. 2007). 
However,  the  building  of  an  in-house  facility  is  time-consuming  and 
expensive.  A  commercial  scale  biopharmaceutical  manufacturing  facility 
normally takes 3 to 4 years to establish, including the design, procurement, 
construction, process qualification and validation (Thiel 2004). Fixed capital 
cost  for  building  a  biopharmaceutical  manufacturing  plant  capable  of 
producing 50kg therapeutic protein annually is €300 million to €500 million 
with  an  up-front  €100  million  for  commissioning  (Werner  2004).  The 
capital  investment  for  building  a  facility  with  six  15,000L  large-scale 
bioreactors on mAb production is $500 million, and $125 million if using 
disposables and reduce the scale to 2000L (Kelley 2009). Such costs have to 
be taken into consideration when making management decisions.  
1.3.3  Contract manufacturing 
The time factor for R&D of biopharmaceuticals is critical, as developers 
need to recover their investment by pushing products to market. Because of 
the  lengthy  construction  time  for  building  a  commercial  manufacturing 
facility, drug developers have to plan the fixed capital investment a long 
time before materials are required for the market. Given the uncertainties in 
clinical trial outcomes, it is likely that several companies have invested in 
building manufacturing facilities for a product that eventually failed to reach 
the  market.  Under  such  circumstances,  CMOs  can  provide  a  solution  to 
respond to changing capacity needs caused by development uncertainties.  
The batch cost of using a CMO to produce mAb is estimated at $3 million at 
the 15,000L bioreactor scale (Kelley 2009). Unlike using in-house facilities, 
the payment to a CMO is up-front and upon delivery, therefore creating 
discrete  cash  flow  rather  than  continuous  cash  flow.  But  compared  to 
building  in-house  GMP  standard  large-scale  manufacturing  facilities,  the 
cost of using a CMO is significantly less.  Chapter 1  
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1.4  SALES OF EXISTING APPROVED HUMANIZED AND FULLY 
HUMAN MAB THERAPEUTICS 
The  sales  data  of  existing  approved  humanized  and  fully  human  mAb 
therapeutics  were  extracted  from  published  reports  from  the  innovator 
companies. Revenues from selling the products across all existing markets 
were included in the annual sales figure, some of which were transformed 
into US dollars using the exchange rate in the corresponding year when the 
report  was  produced.  These  consolidated  sales  figures  for  approved 
humanized  and  fully  human  mAb  therapeutics  from  1998  to  2009  are 
presented  in  Table  1.8.  Among  these  FDA  approved  mAbs,  Humira, 
Avastin, Tysabri, Synagis, Lucentis and Herceptin can be categorized as 
blockbusters (annual sales exceeds $1 billion), Vectibix, Campath, Cimzia, 
Raptiva and Xolair can be categorized as medium products (annual sales 
exceeds  $100  million),  while  Zenapax  and  Soliris  can  be  categorized  as 
niche products (annual sales below $100 million). 
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(Continued) Note: a – figures extracted from Abbott annual report; b – figures 
extracted from Amgen annual report; c – figures extracted from ILEX Oncology 
annual report; d – figures extracted from Genentech annual report from 2004 to 
2008, 2009 figure extracted from Roche annual report adjusted by exchange rate 
CHF:USD; e – figures extracted from UCB annual report adjusted by exchange 
rate EUR:USD; f – Roche annual report adjusted by exchange rate CHF:USD; g – 
figures extracted from Alexion annual report, in $; h – figures extracted from 
Genentech annual report from 2003 to 2008 and Roche annual report 2009, 
adjusted by exchange rate CHF:USD; i – figures extracted from Elan annual report; 
j – figures extracted from Genentech annual report from 2003 to 2008 and Roche 
annual report 2009, adjusted by exchange rate CHF:USD; k – figures extracted 
from MedImmune annual report from 1998 to 2006 and AstraZeneca annual report 
from 2007 to 2009; l – figures extracted from Genentech annual report from 2006 
to 2008 and Roche annual report 2009 adjusted by exchange rate CHF:USD; m – 
figures extracted from Genentech annual report 1998 and Roche annual report from 
1999 to 2009 adjusted by exchange rate CHF:USD. 
 
1.5  MODELING AND OPTIMIZATION APPROACHES 
Optimization  of  portfolio  management  decisions  for  the  development  of 
new biopharmaceuticals requires an accurate and comprehensive capture of 
the  critical  factors  involved  in  this  process.  Modeling  and  simulation 
techniques  using  fast  programming  tools  are  capable  of  incorporating 
numerous critical factors and constructing inter-relations of these factors, as 
well as the uncertainties. Therefore, by providing fast construction of real 
case  scenarios,  decision-makers  can  see  the  consequences  of  alternative 
choices.  Beyond  that,  using  heuristic  optimization  algorithms,  these 
alternatives  can  be  compared,  selected  and  combined  in  such  way  that 
advanced  solutions  can  be  generated.  Optimization  of  decisions,  or 
combination of decisions is made possible by combining model simulation 
with optimization algorithms.  
Portfolio  management  and  capacity  planning  are  vital  to  the  success  of 
pharmaceutical and biopharmaceutical developers. Hence there is a need for 
suitable  tools  that  facilitate  the  decision-making  process  in  these  fields. 
Simulation-based tools are useful due to their ability to generate the likely 
outcomes of a given decision, from which further analyses can be performed. 
Rajapakse et al. (2005) proposed a computer-aided simulation tool to model 
the  biopharmaceutical  drug  development  pathway,  comparing  portfolio 
NPVs of various decision-making scenarios. A further study incorporating Chapter 1  
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Monte  Carlo  simulation  to  capture  the  inherent  uncertainties  in  drug 
development such as development time, COG, and yield, was developed to 
more accurately establish portfolio risk-reward characteristics (Rajapakse et 
al. 2006). George et al. (2007) proposed a multi-criteria decision-making 
framework to provide a holistic evaluation of capacity sourcing decisions 
from both financial and operational perspectives. While simulation-based 
tools  have  demonstrated  their  capability  of  linking  a  decision  with  its 
outcomes,  the  decision-maker  is  usually  confined  to  the  limited  choices 
provided by the scenario analysis. Therefore, optimization-based tools were 
developed  to  search  large  decision  spaces  for  the  optimal  decisions  that 
otherwise  may  be  hidden  from  the  decision-maker.  Broadly,  these 
optimization  tools  use  either  mathematical  programming  methods  or 
heuristic algorithms. The former transforms the problem into mathematical 
formulas and feeds them into a computational solver for optimal solutions, 
whereas the latter makes slight modifications to existing decisions in an 
iterative fashion based on concepts such as evolutionary selection.  
Mathematical programming is often applied to the capacity planning and 
supply chain management problems. Papageorgiou et al. (2001) proposed an 
MILP  formulation  of  pharmaceutical  supply  chain  management  problem 
that  takes  into  account  the  manufacturing  of  API  and  the  global  trading 
structures.  This  deterministic  model  is  capable  of  processing  up  to  8 
products  in  the  company’s  portfolio.  Further  developments  of  the  tool 
enabled  it  to  capture  the  uncertainty  in  demand  (Levis  &  Papageorgiou 
2004) and clinical trial outcomes (Gatica et al. 2003). Sousa et al. (2011) 
improved this tool’s capability in processing long-term strategic planning 
problems with large portfolio and multi-production sites by implementing a 
decomposition  algorithm  with  MILP.  Lakhdar  et  al.  (2006)  developed  a 
biopharmaceutical  supply  chain  management  tool  for  planning  and 
scheduling of multiple products in a single facility using MILP, with a focus 
on facility utilization and cost reduction. This tool was later improved by 
adding  the  capability  to  process  multi-facility  problems  under  demand 
uncertainty, as well as to pursue more objectives such as customer service 
level  (Lakhdar  et  al.  2007).  Siganporia  et  al.  (2013)  proposed  an  MILP Chapter 1  
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approach  to  address  multi-site  production  planning  of  biopharmaceutical 
products  with  either  fed-batch  or  perfusion  bioprocesses.  However,  the 
analysis  was  based  on  fixed  product  candidates.  There  have  been  no 
previous  studies  focusing  on  scenarios  in  which  the  decision-maker  is 
exposed to portfolio selection problems with given manufacturing facilities.  
Despite the development of mathematical programming-based optimization 
tools in capacity planning and supply chain management fields, it is not 
used as often in portfolio management scenarios. This may be due to the 
difficulty  of  translating  pipeline  development  performance  into 
mathematical formula. Mathematical programming does not easily provide 
information  beyond  the  optimal  decisions,  which  could  be  obtained  by 
running  a  simulation-based  tool  with  the  given  decision.  To  solve  this 
problem, several tools combining mathematical programming with discrete-
event  simulation  in  portfolio  management  scenarios  were  developed 
(Subramanian et al. 2000; Varma et al. 2007).  
The other approach uses evolutionary algorithm as the heuristics, making 
use  of  simulation-based  tools  and  optimizing  the  decisions  based  on  the 
feedback  from  the  simulation  process.  Blau  et  al.  (2004)  developed  a 
portfolio management tool with a genetic algorithm to select the optimal 
candidate  combination  and  sequence  of  development.  George  &  Farid 
(2008a)  proposed  a  stochastic  optimization  framework  that  incorporates 
decisions  in  portfolio  selection,  activity  scheduling,  and  outsourcing  in 
clinical research and manufacturing. Probabilistic model building genetic 
algorithms  using  Bayesian  networks  were  used  here  to  solve  the 
combinatorial  optimization  problem.  The  tool  optimizes  the  solutions 
towards higher potential reward in terms of portfolio ENPV and lower risk 
of NPV below zero. This tool was extended to be capable of incorporating a 
minimum  NPV  constraint  in  its  optimization  process  (George  &  Farid 
2008b).  
Although these studies have demonstrated the possibilities of using various 
tools to push the boundaries of portfolio management and capacity planning, 
they have not focused on the consequences of the optimal solutions on the Chapter 1  
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budget  distribution  across  the  various  activities  such  as  clinical  trials, 
manufacturing,  and  process  development.  Importantly,  these  details  are 
essential to benchmark and enhance the understanding of the implications of 
certain decisions.  
Simulation and optimization techniques are also featured in mAb process 
economics tools. Farid et al. (2005) developed a decision-support tool for 
antibody manufacturing to facilitate the decision between stainless steel and 
disposable facilities under different product demands and titres. Lim et al. 
(2006) compared fed-batch with perfusion culture for mAb processing from 
COG and capital investment perspectives. This approach incorporates the 
uncertainties in titre and yield with Monte Carlo simulation. Pollock et al. 
(2013) made use of stochastic discrete-event simulation to compare process 
economics between fed-batch and perfusion cell culture. Using the same 
technique, Stonier et al. (2012) developed a decision-support tool to assess 
the  process  robustness  of  chromatography  options  used  in  antibody 
purification.  MILP  and  MINLP  were  also  featured  in  biopharmaceutical 
facility design, especially in optimal chromatography process design (Liu et 
al. 2013a; Liu et al. 2013b). Simaria et al. (2012) developed a multi-level 
decision-making tool using genetic algorithms to facilitate chromatography 
sequence  and  column  size  optimization.  Allmendinger  et  al.  (2014) 
introduced  an  evolutionary  algorithm  for  optimizing  mAb  purification 
chromatography sequence and column sizing towards multiple objectives 
including  COG/g,  process  robustness,  and  capability  of  removing  the 
impurities.  
The decision-maker can also make use of several commercially available 
solutions  for  optimization  and  simulation  purposes.  The  Decision  Tools 
Suite from Palisade is a general-purpose decisional tool based on Microsoft 
Excel, which uses Monte Carlo simulation for stochastic modeling, and is 
capable of implementing decision tree, neural networks, and evolutionary 
algorithms  for  various  decision-making  scenarios.  As  the  tool  is  Excel-
based, it is not ideal for performing rapid data manipulation on a large scale, 
though  it  can  be  useful  for  product  prototyping.  Phoenix  from  Certara 
(formerly  Pharsight)  is  a  clinical  trial  modeling  software  platform  for Chapter 1  
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processing  pharmacokinetic,  pharmacodynamics,  and  toxicokinetic  data. 
Aspen  Economic  Evaluation  package  from  Aspentech  is  a  multipurpose 
chemical process optimization and economic evaluation software. BioSolve 
from  Biopharm  Services,  a  biopharmaceutical  manufacturing  process 
simulation software based on Microsoft Excel, provides the user with the 
flexibility  of  changing  scale  from  lab  to  commercial,  and  is  capable  of 
rapidly establishing processes that can be configured as vaccine or mAb 
processes. It creates a dashboard-like process report that includes economic 
metrics.  
1.6  AIM AND ORGANIZATION OF THESIS 
The previous sections presented a description of the main subjects of the 
biopharmaceutical drug development process that are involved in portfolio 
management  decision-making,  emphasizing  the  key  factors  and 
methodology  that  drive  the  decision-making  process.  Modelling  and 
optimization  approaches  addressing  the  above  factors  are  reviewed  with 
attention to their techniques and application scenarios. Despite the coverage 
of existing research on the subject, a portfolio management decision-making 
tool that provides full flexibility towards candidate selection and provides 
reports  on  critical  portfolio  cost  characteristics  for  capacity  and  budget 
planning is still absent.  
The aim of this thesis is therefore to develop computational decision tools 
that produce quality solutions to biopharmaceutical portfolio management 
problems  under  changing  circumstances,  and  to  provide  guidance  to  the 
related  implementation  issues  from  a  cost  evaluation  prospective.  The 
remainder of the thesis is structured around achieving this goal.  
In Chapter 2, a drug development lifecycle cost model is proposed for the 
purpose  of  cost  evaluation  of  biopharmaceutical  portfolio  development. 
Monte Carlo simulation and dynamic simulation mechanisms are integrated 
in  this  activity-based,  object-oriented  tool  to  enable  the  capability  of 
allocating  resources  under  development  uncertainties.  A  bespoke  multi-
objective  evolutionary  algorithm  is  created  so  as  to  optimize  portfolio Chapter 1  
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management decisions based on their calculated risk-reward characteristics. 
Features  such  as  the  data  management  system  that  produces  reports 
regarding  the  performance  of  solutions,  and  the  details  of  the  drug 
development process are also described in this chapter. 
Cost evaluation of biopharmaceutical portfolio development using the drug 
development lifecycle cost model is presented in Chapter 3. Benchmarks of 
industrial average costs of developing a single product and a portfolio of 
products aiming at one market success per year are generated, with special 
attention to the cost spent on non-clinical activities. Scenarios that feature 
optimistic  and  pessimistic  assumptions  of  drug  success  rates  are  also 
investigated, with various sources of out-of-pocket development costs. An 
analysis  of  the  implications  of  drug  development  delay  in  the  portfolio 
context discovers the cost of managing the delay at a tolerable level.  
Based on the cost benchmarks produced in Chapter 2, the implementation of 
the  stochastic  optimization  tool  for  biopharmaceutical  portfolio 
management  decision-making  is  presented  in  Chapter  3.  A  hypothetical 
candidate  pool  is  formulated  with  products  of  distinct  risk-reward 
characteristics. Portfolio management decisions are optimized under various 
budget  and  capacity  constraints,  and  the  trends  of  optimal  solutions  are 
investigated, as well as their cost distribution details across the development 
timeline. The candidate pool is further diversified by introducing product 
candidates that are more advanced in the development process, but require 
upfront cost to develop. Optimization of portfolio management decisions 
under different budgets and upfront payments is explored, with the analysis 
on critical decision boundaries regarding the acquisition of outside products. 
In Chapter 5, the application of the drug development lifecycle cost model 
focuses on the emerging cell therapy industry. The differences in clinical 
trial,  manufacturing,  and  process  development  activities  between  cell 
therapy and biopharmaceutical products are reviewed and the related costs 
are  estimated.  Cost  evaluation  of  cell  therapy  portfolio  development  is 
performed and the results compared against those for biopharmaceuticals. 
Estimations of cell therapy market potential and gross margin are made to Chapter 1  
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extend the analysis of portfolio expected NPV and its vulnerability against 
delays in late stage development due to the potential market competitions. 
Finally,  Chapter  6  summarizes  the  main  contribution  of  this  work  and 
discusses likely directions for future work. 
 CHAPTER 2   
COMPUTATIONAL DECISION TOOLS FOR STOCHASTIC 
OPTIMIZATION AND COST EVALUATION OF 
BIOPHARMACEUTICAL PORTFOLIO DEVELOPMENT  
2.1  INTRODUCTION 
As  discussed  in  the  previous  chapter,  studies  on  biopharmaceutical  cost 
modelling have been focusing on total stage costs and overall out-of-pocket 
and capitalized costs, rather than how these costs distribute across clinical 
and non-clinical activities. In this chapter, a drug development lifecycle cost 
model is proposed to capture the cost distribution characteristics in drug 
portfolio  development  by  decomposing  drug  development  stages  into 
clinical  trials,  manufacturing,  and  process  development  activities.  More 
detailed  implementations  of  this  cost  evaluation  tool  are  presented  in 
Chapter 3 and Chapter 5, featuring portfolio development of pharmaceutical, 
biopharmaceutical, and cell therapy products.  
Based on this drug development lifecycle cost model, an improved portfolio 
development model was designed, with Monte Carlo simulation to capture 
the effect of uncertainties and dynamic simulation to model the resource 
allocation process. This model was implemented as the evaluation engine of 
the stochastic optimization tool, which could be used to support portfolio 
management  decision-making  by  providing  appraisals  for  strategic 
decisions. A multi-objective evolutionary algorithm (MOEA) was adapted 
from the publicly available jMetal package (Durillo & Nebro 2011) and 
tailored  to  facilitate  the  decision-making  of  biopharmaceutical  portfolio 
management. The algorithm inherits the concept of NSGA-II (Deb et al. 
2002) and uses NPV distributions provided by the portfolio development 
model  as  objectives  for  optimization.  A  binary  string  representation  of 
decision  variables  was  designed  as  the  solution  structure  to  allow  the 
selection of any number of product candidates into the R&D portfolio. The Chapter 2 
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implementation of this stochastic optimization tool is presented with various 
candidate pools in Chapter 4. 
The remainder of this chapter is structured as follows. Section 2.2 describes 
the overall structure of the optimization tool, whose main components are 
separately  described  in  the  following  3  sections.  The  evaluation  engine 
based on the drug development lifecycle cost model is discussed in Section 
2.3.  The  adaptation  of  MOEA  and  its  working  process  is  described  in 
Section 2.4. The design of the output formats of data reports generated by 
the stochastic optimization tool, as well as the tool for data visualisation, are 
presented in Section 2.5.  
2.2  THE OVERALL STRUCTURE OF THE STOCHASTIC 
OPTIMIZATION TOOL 
The stochastic optimization tool for strategic portfolio decision-making in 
biopharmaceutical new product development is comprised of 3 functional 
components: 1) an optimization algorithm, for generating and optimization 
the  strings  representing  portfolio  management  solutions,  which  can  be 
evaluated in 2) the evaluation engine, for evaluating the quality of solution 
by constructing the portfolio development process and simulating cash flow 
performance under resource constraints and uncertainties; and finally, the 
results from the aforementioned components are collected and analysed by 
3)  a  data  management  system.  A  detailed  diagram  illustrating  the 
interactions of these 3 components is presented in Figure 2.1. 
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Several prototypes of the stochastic optimization tool were built either in 
Java  or  in  Excel  with  proprietary  add-in  for  evolutionary  algorithm  and 
Monte Carlo simulations. The pros and cons of these modelling alternatives 
are presented in Table 2.1. Java was chosen as the modelling environment 
primarily  due  to  its  flexibility  and  high  performance,  in  particular  the 
object-oriented features that facilitate the design of activity-based portfolio 
development lifecycle, although it lacks instant database solution and data 
visualization  tools.  Nonetheless,  Excel  was  useful  for  model  prototyping 
since its build-in formulae and charts allow quick analysis of the results, 
which  can  help  understanding  model  logics  and  identifying  key  design 
pitfalls.  
Table 2.1 Pros and cons for Java and Excel as modelling environment.  
Java  Excel 
Object-oriented, highly flexible  Spread-sheet based, semi-flexible 
(require using VBA for in-depth 
design) 
Professional package for implementing 
evolutionary algorithm, available for 
public 
Proprietary add-ins for genetic 
algorithm 
High performance with Java virtual 
machine 
Relatively slower 
Portable, cross-platform  Available exclusively on PC and Mac 
systems 
No integrated database  Integrated database with spread-sheet 
functionality 
Requires outside tools for data analysis 
and visualization 
In-house data analysis and 
visualization 
Requires outside tools for collaborative 
development 
Collaborative development achieved 
by Microsoft online services 
Note: The features of Java programming language described here is representative 
for most object-oriented programming language such as C#. Most of the features of 
Excel in this table can also be used to describe numerical computing tools such as 
MATLAB in terms of modeling biopharmaceutical portfolio development. 
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2.3  THE EVALUATION ENGINE 
The role that the evaluation engine played in the stochastic optimization tool 
was  to  provide  an  assessment  of  a  single  solution  in  terms  of  two  key 
statistics of the NPV distribution, namely the average positive NPV and the 
probability of NPV being positive. A drug development lifecycle cost model 
was developed as the backbone of the evaluation engine that provided fast 
characterization of cost distributions of portfolio development for certain 
product categories. The model first established development pathways for 
products within the portfolio, then scheduled all related activities of clinical 
trials, manufacturing, and process development for either cost evaluation, or 
the more sophisticated Monte Carlo simulation if stochastic optimization 
was  required.  A  schematic  of  the  running  mechanism  of  the  evaluation 
engine is presented in Figure 2.2, in which the drug development lifecycle 
cost model is surrounded by dash lines.  
As illustrated in Figure 2.2, the scope of simulation and modelling for this 
evaluation  engine  was  limited  to  the  activity  level  and  above.  The  core 
elements of simulation were the components of drug development lifecycle, 
namely the clinical trial, manufacturing, and process development activities. 
This  evaluation  engine  did  not  model  the  manufacturing  process  of  a 
particular product explicitly, nor did it model the supply chain characteristic 
for transferring bulk materials from manufacturing facilities to clinical trial 
sites.  Under  the  scope  of  this  work,  the  more  detailed  simulations  were 
considered  to  be  of  little  impact  to  the  overall  performance  of  portfolio 
development decision-making, though they do matter in reality. Variations 
generated in Monte Carlo simulations regarding the durations and costs of 
activities can be seen as the results of different manufacturing practises or 
supply chain management decisions. Therefore the user can place his/her 
attention on the drug development lifecycle activities and how they interact 
with the resource constraints.   
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2.3.1  The drug development lifecycle cost model 
The design of the drug development lifecycle cost model followed a top-
down,  activity-based  approach.  It  created  objects  to  represent  the  drug 
developing company, the drug candidates, and the activities that needed to 
be carried out in the development lifecycle. The object-oriented design of 
the  classes  is  described  in  the  following  paragraphs,  focusing  on  their 
specific fields and methods. The description format in these paragraphs also 
follows the naming convention that uses concatenated words each starting 
with  upper  case  to  represent  class  names,  and  lower  case  separated  by 
underscores to represent object and method names.  
Table 2.2 presents the key aspects in designing the “Company” class for the 
drug development lifecycle cost model. This class has its specific attributes 
such as the list of portfolio products and manufacturing facilities. It also 
functions to assemble portfolio products based on the values of decision 
variables.  The  resource  attributes,  i.e.  the  budget  and  manufacturing 
facilities, were inactivated during cost evaluation process.  
Table 2.2 Key aspects of object-oriented design of the “Company” class.  
Field type  Field name   
String  name  As the identifier of the company 
object. 
List<Drug>  drugs  The list of portfolio products. 
Budget  budget  The company’s annual R&D budget. 
double  cost_of_capital  The discount factor employed by the 
company for calculations of DCF and 
NPV. 
List<ManuFacility>  mfs  The list of manufacturing facilities 
within the company. 
Method return type  Method name 
(argument) 
 
void  assemble_drugs 
(int[] decisions) 
Take portfolio management decisions 
as input, assemble drugs into 
development portfolio. 
Note:  The  fields  and  methods  presented  in  this  table  do  not  include  common 
object-oriented programming elements such as object constructor. Chapter 2 
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Following the construction of a company object, several drug objects were 
created  with  key  design  aspects  described  in  Table  2.3.  Drug  specific 
attributes such as starting stage and market potential were included, as well 
as the method to assemble all relevant development activities from clinical 
trial, manufacturing, and process development into a list of activities.  
Table 2.3 Key aspects of object-oriented design of the “Drug” class.  
Field type  Field name   
int  drug_number  As the identifier of the drug object. 
int  starting_stage  The starting stage of drug, represented 
by integer indexing of development 
stages. e.g. “starting_stage = 0” means 
the drug starts at pre-clinical stage. 
double  market_potential  The value of the drug should it receive 
FDA approval. 
List<Activity>  activities  The list of activities that included in the 
drug development lifecycle. 
boolean  successful  The result of drug development for a 
given Monte Carlo simulation. This and 
the following 2 attributes are reset for 
every Monte Carlo simulation. 
int  time_to_market  The time of drug receiving FDA 
approval to market. 
int  current_stage  The current development stage of the 
drug. It is updated every time the drug 
enters another development stage. 
Method return 
type 
Method name 
(argument) 
 
void  assemble_activities()  Construct the drug development 
lifecycle by assembling activities of 
clinical trial, manufacturing, and 
process development. 
void  reset()  Reset the drug development status for 
every Monte Carlo simulation. 
Note: The fields and methods presented in this table do not include common 
object-oriented programming elements such as object constructor. 
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There were fields reserved for the drug object to record its development 
status during the running of Monte Carlo simulations including the result of 
development, the timing of product market approval, and the current stage 
of development. These fields were reset for every Monte Carlo simulation 
and inactivated when running the application for cost evaluation purpose.  
Activities created by the drug objects can be divided into 3 distinct sub-
classes, clinical trial, process development, and manufacturing. They were 
all inherited from the abstract “Activity” class described in Table 2.4. The 
key  features  that  the  design  of  the  “Activity”  class  enables  in  drug 
development lifecycle cost model were the capability of distinguish costs 
from  various  origins  and  fast  scheduling  of  activities  according  to  their 
dependencies.  Once  the  scheduling  of  activities  was  finished,  portfolio 
development cash flow can be generated for cost evaluation purpose.  
A large portion of design aspects of the “Activity” class was dedicated to 
accommodate Monte Carlo simulation and dynamic simulation in stochastic 
optimization. This included the actual timing of activities, the mechanisms 
regarding  the  triggering,  progression,  and  finishing  of  the  activities,  and 
interruptions  whenever  the  project  fails.  These  are  discussed  in  the 
following sub-sections.  
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Table 2.4 Key aspects of object-oriented design of the “Activity” class.  
Field type  Field name   
Drug  drug  The drug it belongs to. 
int  stage  The integer indexing of development 
stage it belongs to. 
String  activity_type  The type of activity (clinical trial, 
manufacturing, or process 
development). 
int  duration  The duration of activity. 
int  cost  The total cost of activity 
boolean  starting  If the activity is the starting activity of 
development lifecycle. 
Activity  next  Next activity. 
int  time_start  The planned starting time of activity. 
int  time_start_s  The actual starting time of activity. For 
each Monte Carlo simulation, the 
starting time of activity can be different 
due to delays from previous activities 
or lack of resources.  
int  time_end_s  The actual end time of activity. 
int  elapsed_time  The actual elapsed time of activity 
during dynamic simulation. 
boolean  triggered  Record the status of activity during 
dynamic simulation. 
Method return 
type 
Method name 
(argument) 
 
boolean  triggering()  Checking if the conditions of activity 
starting are met. If yes, start the 
activity. 
int  progressing()  Activity progression in dynamic 
simulation. Effective progression 
returns the associated cost and 
increases the elapsed time of activity. 
boolean  interrupted()  The activity gets interrupted when 
product fails in clinical trials. 
boolean  finishing()  Activate the finishing process when 
elapsed time equals the duration of 
activity.  
void  reset()  Reset development status. 
Note:  The  fields  and  methods  presented  in  this  table  do  not  include  common 
object-oriented  programming  elements  such  as  object  constructor  or  the  ones 
created for data collection purposes. 
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2.3.2  Monte Carlo simulation 
Monte Carlo simulation is implemented here to address the uncertainties in 
the  various  stochastic  inputs,  including  clinical  trial  lengths  and  costs, 
product  market  potentials,  and  most  importantly,  the  pass/fail  result  of 
clinical trials. Random values are generated to represent such uncertainties 
based  on  assumptions  of  their  distributions.  For  quantitative  stochastic 
parameters such as duration of activities, product market potential, and costs, 
this  tool  is  capable  of  generating  random  numbers  following  Gaussian, 
triangular,  and  Poisson  distributions,  the  selection  among  which  can  be 
altered by user requirement. For the pass/fail result of clinical trials, the tool 
generates binary random values based on the phase transition probabilities. 
The random values are only generated when they are needed for efficiency 
consideration. Since during the simulation of portfolio development process 
many  activities  may  not  even  be  triggered,  it  would  be  a  waste  of 
computation time to prepare random values for their stochastic parameters. 
The market potential information is generated when the drug obtains FDA 
approval. Similarly the costs and durations of activities are generated only 
when the activities are triggered, and the pass/fail results of clinical trials are 
generated at the end of clinical trials. The random values are removed once 
a new Monte Carlo simulation is initiated by the “reset()” method included 
in the key design aspects of company, drug, and activity classes. At the 
same time, a new random number generator is created with a different seed 
to maintain the randomness. 
To determine the sufficient number of Monte Carlo simulations needed for 
providing  full  coverage  of  NPV  distributions,  the  running  average  of 
portfolio NPV is analysed for 20 distinct solutions with uncertainties from 
clinical  trial  results.  Figure  2.3  shows  the  convergence  of  NPVs  as  the 
number  of  Monte  Carlo  trials  increases.  In  most  situations,  the  NPVs 
converge  before  100  trials.  Increasing  the  number  of  Monte  Carlo 
simulations from 100 provides little improvement in terms of capturing the 
distribution  of  NPVs.  However,  it  may  be  necessary  to  re-configure  the Chapter 2 
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number of Monte Carlo trials as the level of uncertainty changes, or when 
additional mechanism that complicates the process is introduced.  
 
Figure 2.3 Cumulative running averages of NPVs throughout multiple Monte 
Carlo simulations.  
This is a fraction of a bigger graph consists of 20 cumulative running average plots 
for 20 different solutions. The x-axis is the number of Monte Carlo trials and y-axis 
is the cumulative running average of NPVs for existing number of Monte Carlo 
trials. 
 
2.3.3  Dynamic simulation with resource constraints 
The introduction of uncertainties makes it impossible to predict the exact 
timing  of  activities  during  the  simulation  of  biopharmaceutical  portfolio 
development  process.  The  problem  is  further  complicated  by  the 
requirement to allocate resources between activities based on their timing 
precedence. Therefore, a dynamic simulation approach was proposed under 
the activity-based framework of drug development lifecycle cost model to 
represent how biopharmaceutical portfolio development takes place. This 
approach  breaks  up  the  time  into  small  slices  and  updates  the  states  of 
activities by moving the time horizon from one slice to another.  
This  approach  can  be  implemented  by  using  commercial  simulation 
packages  capable  of  dynamic  continuous  simulation  like  ExtendSim. Chapter 2 
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However,  the  software  is  overly  complex  compared  to  the  simulation 
requirement of this approach. It is not economical to make the purchase 
without using most of its functions. In addition, the level of control over the 
simulation process cannot be fulfilled by the proprietary software without 
the proper application interface with other modules of the tool. Therefore 
dynamic simulation is purposely built into this tool. 
Before initiating the dynamic simulation, critical starting times need to be 
established for activities that do not depend on other activities to start. This 
is  accomplished  by  the  scheduling  procedure  in  the  drug  development 
lifecycle  cost  model,  and  is  based  on  the  planned  durations  of  and  the 
dependencies between the activities. The dynamic simulation process takes 
the planned starting time of the independent activities as their actual starting 
time.  For  other  activities,  their  timings  will  be  determined  during  the 
running of dynamic simulation. The scheduling procedure runs only once 
during the evaluation of one solution for efficiency considerations.  
The Monte Carlo simulations start when the scheduling procedure finishes. 
For each Monte Carlo simulation, the dynamic simulation moves the time 
horizon from the starting point of portfolio development to a given future 
time specified by the user.  
The dynamic simulation implemented here updates all activities for each 
time  slice  by  invoking  their  triggering,  progression,  and  finishing 
mechanisms, which were built into the model. Activities are divided into 
categories where they inherited the abstract methods from the “Activity” 
class,  but  the  implementation  of  these  methods  differs.  The  three  major 
categories and their mechanisms are presented as follows. 
•  Category 1: Clinical trials 
The clinical trial activity category includes all the activities that trigger a 
pass/fail judgment at the end of their duration. By this definition, activities 
such  as  pre-clinical  trials  and  FDA  reviews  are  also  included  in  this 
category, even though they are not actual clinical trials. Another feature of 
clinical trial activities is that they are normally on the drug development Chapter 2 
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critical  path.  The  triggering,  progression  and  finishing  mechanisms  of 
clinical trial activities are shown in Figure 2.4.  
The triggering mechanism first checks if the activity is already triggered, 
and if not, it will then check if the activity meets the triggering conditions. 
For clinical trial activities, the triggering conditions normally include 1) the 
corresponding  manufacturing  activity  has  finished  to  supply  the  required 
material,  and  2)  the  previous  clinical  trial  has  finished  and  the  result  is 
successful. All satisfied, the clinical trial activity is then triggered, and the 
actual start time is set to the current time and activity elapsed time is set to 0.  
For an already triggered clinical trial activity, the progression mechanism is 
activated instead. Progression mechanism checks if there is enough budget 
left for the activity to carry on. If yes, the consumption is deducted and the 
progression is recorded by increasing the elapsed time by 1 unit time. The 
mechanism also reports the incurring cost to cash flow data collection.  
The finishing mechanism is invoked once the activity elapsed time equals its 
duration.  For  a  clinical  trial  activity,  the  pass/fail  result  is  produced  by 
generating a uniformly distributed random number between 0 and 1 and 
comparing it to the phase transition probability of the activity. If the latter is 
smaller, the activity fails. The finishing mechanism also sets the current 
time as the activity’s actual end time and changes the value of end status to 
true to prevent re-invoking the progression mechanism in the next unit time. 
If the activity passes, the triggering condition will be changed for the next 
activity. Otherwise the finishing mechanism will shut down the project by 
calling the “interrupted” method of all concurrent activities for this product. 
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•  Category 2: Manufacturing 
Manufacturing  activities  are  defined  as  the  activities  that  require 
manufacturing  facilities  to  start.  The  design  of  the  dynamic  simulation 
mechanisms of manufacturing activities is presented in Figure 2.5.  
Similar  to  clinical  trial  activities,  the  triggering  mechanism  of  a 
manufacturing activity first checks if the activity is already triggered, then 
checks if the activity meets its triggering conditions, which in this case is 
the successful completion of corresponding process development activity. 
The  triggering  mechanism  of  manufacturing  differs  from  that  of  clinical 
trials in that even if all conditions are satisfied, it requires spare facility to 
start.  The  idle  facility  that  the  company  has  access  to  will  be  marked 
“occupied” once it undertakes the manufacturing activity. The progression 
mechanism of manufacturing activities is exactly the same as the one of 
clinical trial activities. The finishing mechanism is invoked once the elapsed 
time equals the duration of activity. The finishing of manufacturing activity 
does not require randomly generated number to decide whether the activity 
is successful; instead, it releases the manufacturing facility by changing its 
status  from  “occupied”  to  “idle”  so  that  it  is  able  to  undertake  other 
manufacturing tasks. Completion of a manufacturing activity changes the 
triggering condition of its next activity, clinical trial in most cases.  
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•  Category 3: Process development 
Similar to clinical trial activities, the process development activities only 
require one resource for its progression, the budget. The key distinction of 
process development activities is that they do not depend on other activities 
to  start.  Their  start  times  for  dynamic  simulation  are  established  by  the 
scheduling procedure that plans the activities based on the need of clinical 
trials.  Hence  the  triggering  condition  for  process  development  activities 
only requires that the current time is the planned start time.  
Figure  2.6  illustrates  the  state  changes  for  activities  from  clinical  trial, 
manufacturing,  and  process  development  in  an  example  of  dynamic 
simulation.  Activity  A  and  C  are  triggered  from  the  start  because  they 
require no previous activities. They remain triggered until unit time 3 when 
Activity  C  is  finished,  which  changes  the  triggering  condition  for  its 
successor, Activity D. When unit time 4 hits, Activity D is triggered as its 
triggering conditions are met. In this particular example, because the length 
of Activity D is only 1 unit time, the finishing time of Activity D coincides 
with  that  of  Activity  A,  making  all  triggering  conditions  satisfied  for 
Activity B. Had the random generator produced a slightly longer duration 
for Activity D, Activity B would be delayed due to a lack of material supply 
from  its  corresponding  manufacturing  activity.  On  the  other  hand,  if 
Activity A lasts a little longer, Activity B can not be triggered either since 
one of the triggering conditions for clinical trials is that the previous trial 
must have finished. At unit time 5, Activity B is triggered and it progresses 
through the rest of unit times in the diagram. The states of Activities A, C, 
and D are all “end” so their progression mechanism cannot be activated.  
The setup of the tool defines that the durations of activities are positive 
integer values, with the unit time being 1 week. Therefore, the durations of 
activities  illustrated  in  Figure  2.6  are  all  multiples  of  a  week.  Further 
dividing the unit time is considered unnecessary at this level of simulation. 
   Chapter 2 
  58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
i
g
u
r
e
 
2
.
6
 
T
y
p
i
c
a
l
 
s
t
a
t
e
 
c
h
a
n
g
e
s
 
f
o
r
 
a
c
t
i
v
i
t
i
e
s
 
f
r
o
m
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
,
 
m
a
n
u
f
a
c
t
u
r
i
n
g
,
 
a
n
d
 
p
r
o
c
e
s
s
 
d
e
v
e
l
o
p
m
e
n
t
 
i
n
 
d
y
n
a
m
i
c
 
s
i
m
u
l
a
t
i
o
n
.
 
 
F
o
r
 
e
a
c
h
 
M
o
n
t
e
 
C
a
r
l
o
 
s
i
m
u
l
a
t
i
o
n
,
 
t
h
e
 
d
y
n
a
m
i
c
 
s
i
m
u
l
a
t
i
o
n
 
u
p
d
a
t
e
s
 
t
h
e
 
s
t
a
t
e
s
 
o
f
 
a
c
t
i
v
i
t
i
e
s
 
b
y
 
i
n
v
o
k
i
n
g
 
t
h
e
 
t
r
i
g
g
e
r
i
n
g
,
 
p
r
o
g
r
e
s
s
i
o
n
,
 
a
n
d
 
f
i
n
i
s
h
i
n
g
 
m
e
c
h
a
n
i
s
m
 
f
o
r
 
e
a
c
h
 
u
n
i
t
 
t
i
m
e
 
p
a
s
s
i
n
g
.
 
D
e
p
e
n
d
e
n
c
i
e
s
 
b
e
t
w
e
e
n
 
a
c
t
i
v
i
t
i
e
s
 
a
n
d
 
t
h
e
 
a
v
a
i
l
a
b
i
l
i
t
y
 
o
f
 
r
e
s
o
u
r
c
e
s
 
i
n
 
t
e
r
m
s
 
o
f
 
b
u
d
g
e
t
 
a
n
d
 
m
a
n
u
f
a
c
t
u
r
i
n
g
 
f
a
c
i
l
i
t
y
 
d
e
t
e
r
m
i
n
e
 
t
h
e
 
t
r
i
g
g
e
r
i
n
g
 
c
o
n
d
i
t
i
o
n
s
.
 
I
n
 
t
h
i
s
 
d
i
a
g
r
a
m
,
 
i
t
 
i
s
 
a
s
s
u
m
e
d
 
t
h
a
t
 
t
h
e
r
e
 
a
r
e
 
s
u
f
f
i
c
i
e
n
t
 
b
u
d
g
e
t
 
a
n
d
 
f
a
c
i
l
i
t
y
 
t
o
 
s
u
p
p
o
r
t
 
a
c
t
i
v
i
t
i
e
s
 
f
r
o
m
 
A
 
t
o
 
D
.
 Chapter 2 
  59 
2.4  THE OPTIMIZATION ALGORITHM 
The purpose of optimization algorithm is to efficiently search the decisions 
space and find the optimal solutions based on the appraisals provided by the 
evaluation engine. As described in previous subsections, the simulation of 
biopharmaceutical  portfolio  development  lifecycle  with  uncertainties  and 
resource constraints involves complex mechanisms that pose a challenge to 
conceptually formulating the problem in mathematical form. With the entire 
evaluation engine being activity-based, a more intuitive approach is to use 
genetic algorithm as a search heuristic for finding the optimal solutions. 
This approach also has the following advantages. 
•  Genetic algorithm can achieve relatively fast convergence to global 
optimum regardless of the fitness landscape. The mutation operation 
performed  during  the  replacement  of  the  previous  generation  of 
solutions enables random drift from the local optima.  
•  The repeated fitness function evaluation feature of genetic algorithm 
fits well with the Monte Carlo simulation, as the increased number 
of evaluation improves the quality of fitness value. Meanwhile, the 
evaluation process is fast with the activity-based evaluation engine, 
presenting the repeated evaluation as the performance bottleneck of 
the tool. 
•  For the portfolio management problem, the design of integer-based 
solution structure is simple and intuitive. Unlike problems with real 
number solutions, integer-based solution in genetic algorithm does 
not need further translation. It is a direct representation of strategic 
portfolio management decision-making. 
•  Genetic algorithm produces an optimal set of solutions so that the 
user of this tool have more options in choosing the best strategy 
based on his/her preference toward implementation. This feature is 
particularly  advantageous  in  the  context  of  multi-objective 
optimization  as  competing  solutions  can  be  presented  within  1 
Pareto optimal front.  Chapter 2 
  60 
Despite these advantages, there are limitations that require special attention 
in the design and implementation of genetic algorithm. First, there are no 
definite termination criteria for the algorithm. The algorithm can in theory 
run forever without having any improvement to its optimization objectives. 
It is therefore necessary to arbitrarily set up a termination criteria based on 
the progression of convergence to a specific problem. A trial run should be 
performed  ahead  of  the  actual  optimization  and  the  progression  of 
objectives should be monitored. A decision on how many generations to run 
can then be reached by comparing the cost of an extra generation against the 
benefit in terms of improvements in objectives.  
Second, to maximize the performance of the algorithm, the user need to set 
up the running parameters for a given problem. These parameters include 
the crossover rate, the mutation rate, and most importantly, the size of the 
population.  Trial  runs  with  different  combinations  of  these  parameters 
should be performed ahead of optimization to explore the optimal setup that 
maximizes  the  improvement  of  objectives  within  a  given  number  of 
evaluations.  
Third, for some solution structures, it is possible that “illegal” solution be 
generated  during  the  optimization  process,  i.e.  solutions  that  are  not 
applicable for evaluation is generated. Evolution strategies are required in 
dealing with these “illegal” solutions. Viable options are 1) eliminating the 
possibility  of  generating  “illegal”  solutions  by  the  specific  design  of 
solution  structure;  or  2)  fixing  the  “illegal”  solutions  so  that  they  are 
applicable for evaluation; or 3) setting up penalty mechanisms when “illegal” 
solutions are generated.  
The first 2 limitations are problem-specific. Therefore they are addressed in 
the implantation of the algorithm. The design of solution structure in this 
tool is inherently immune to the 3
rd limitation as described in the following 
subsection.  
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2.4.1  Solution structure 
Portfolio  management  decisions  typically  concern  the  selection  from  a 
group  of  investment  assets,  in  this  case,  product  candidates  of  various 
characteristics. With each individual product candidate, the key question is 
whether it should be in the development pipeline, given the circumstances 
of the decision maker. Hence a solution structure in the form of a binary 
string with its length equal to the number of product candidates is proposed 
to represent the portfolio management strategy. Each bit of this binary string 
represents a unique product candidate, with the value of this bit representing 
the decision of whether to include this product candidate into the portfolio. 
See Figure 2.7. 
As mentioned before, this design completely eliminates any possibility of 
generating “illegal” solutions as long as all product candidates are eligible 
for  development.  The  design  of  binary  string  as  solution  structure  also 
provides utility in situations where updating product candidate pool happens 
frequently.  The  capability  of  embracing  changes  to  the  candidate  pool 
matters  as  the  ground  is  shifting  every  day  in  modern  pharmaceutical 
industry with new discoveries and technologies emerge rapidly. For every 
new product candidate, the decision-maker can simply add it to the list of 
existing candidates without causing any conflicts.  
Compared to a design of using integers to represent the portfolio selection 
decisions, the binary string representation has the flexibility of choosing any 
number  of  candidates,  therefore  releasing  the  full  potential  that  can  be 
achieved  by  the  optimization  algorithm.  Restrictions  on  how  many 
candidates  to  choose  can  also  be  conveniently  installed  onto  the  binary 
string by limiting the number of 1 value in its bits.  
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From a performance point of view, the binary string solution structure is the 
most  time-saving  in  crossover  and  mutation  operations,  which  can  be 
repeated for thousands of times in running of a genetic algorithm with 100 
generations and 100 solutions in the population.  
The decision space of portfolio management optimization, in the form of 
binary string solution structure, is 2
N where N is the number of candidates 
for selection. Assuming constant time cost for each evaluation, the problem 
is obviously not polynomial time solvable with any algorithm that is based 
on  traversing  through  all  viable  solutions,  justifying  the  use  of 
metaheuristics for more efficient searching of decision space. A medium-
size biopharmaceutical company can easily have a 10-product pipeline. For 
big pharmaceutical companies, their pipeline sizes normally range from 30 
to 100 with compounds from various therapeutic areas at different clinical 
stages.  With  in-licensing  option  enabled,  the  number  of  eligible  product 
candidates  can  reach  30  for  small  and  medium  biopharmaceutical 
enterprises  and  200  for  big  pharmaceutical  companies.  Therefore  the 
maximum  decision  space  for  small  and  medium  biopharmaceutical 
enterprise is around 10
9, for big pharmaceutical companies approximately 
10
60.  
2.4.2  Optimization objectives 
Net  present  value  (NPV)  is  widely  accepted  as  the  key  criterion  for 
investment  decision-making.  The  methodology  of  applying  NPV  rule  to 
decision making is to compare NPVs of all investment strategy alternatives 
and choose the one that gives the highest NPV. For the purpose of this tool, 
the investment strategy alternatives are the solutions to biopharmaceutical 
portfolio development decision-making, which is discussed in the previous 
subsection.  
At the evaluation engine, the tool takes the solution as input and produces 
the  cash  flows  projections  by  performing  Monte  Carlo  simulation  and 
dynamic  simulation.  NPV  can  be  obtained  by  using  the  discounted  cash 
flow method:   Chapter 2 
  64 
𝑁𝑃𝑉 =
𝑅 
(1 + 𝑖) 
 
   
 
Where t is the time when cash flow is generated, 𝑅  is the amount of cash 
flow generated at time t, i is the discount factor, and n is the scope of time 
range of dynamic simulation. As described before, in the drug development 
lifecycle cost model, the R&D expenses are viewed as negative cash flow 
(cash outflow) and the profits from marketing the product are considered 
positive  cash  flow  (cash  inflow).  It  is  possible  for  NPVs  to  be  negative 
because  the  discounted  cash  outflow  may  outweigh  the  discounted  cash 
inflow. In investment terms, the decisions that lead to negative NPVs are 
considered failure in meeting the pre-determined return on investment.  
However,  with  the  integration  of  Monte  Carlo  simulation  capturing  the 
uncertainties inherent in drug development process, instead of one single 
NPV, a distribution of NPVs is produced as results of various runs of cash 
flow projections. Key statistics describing the NPV distribution is adopted 
as the optimization objectives. They are 1) the average of positive NPVs 
(APNPV) and 2) the probability of NPVs being positive (p(NPV>0)). The 
former  represents  the  potential  reward  should  the  NPV  turn  out  to  be 
positive, the latter reflects the possibility of this happening.  
The  rationale  behind  the  selection  of  optimization  objectives  is  twofold. 
First,  the  objectives  should  provide  sufficient  information  regarding  the 
potential profitability and risk of investment decisions. Using APNPV as the 
profitability  indicator  removes  the  effect  of  negative  NPV  and  therefore 
provides a clear picture as to how well the strategy can be on the upside. 
Meanwhile the value of p(NPV>0) suggests the likelihood of result being on 
the  upside.  The  second  point  of  selecting  these  two  statistics  of  NPV 
distribution  is  that  they  are  likely  to  be  conflicting  in  the  context  of 
biopharmaceutical portfolio development, given the risk and cost associated 
with drug development process. Figure 2.8 presents a general categorization 
of biopharmaceutical portfolio development strategies based on their likely 
outcomes  in  these  two  objectives.  The  champion  strategy  triumphs  no 
matter what risk-reward preference the user holds, if such strategy exists. Chapter 2 
  65 
The gambler’s strategy can be competing with the safety strategy as the 
former focuses on potential reward while the latter suffers mediocre reward 
in  exchange  for  safety.  The  selection  between  these  2  strategy  types  is 
entirely dependent on the user preference.  
 
Figure 2.8 The biopharmaceutical portfolio development strategy matrix.  
Strategies of portfolio management decisions are categories by 2 key statistics of 
their respective NPV distributions. The horizontal axis represents the possibility of 
NPV being positive and the vertical axis represents the average value of positive 
NPVs.  
 
The  Pareto  approach  is  implemented  to  overcome  the  difficulties  of 
comparing solutions based on their performances in these 2 objectives. The 
details  of  implementation  of  this  approach  are  described  in  the  next 
subsection.  
2.4.3  NSGA-II 
Non-dominated sorting genetic algorithm II (NSGA-II) is a multi-objective 
evolutionary  algorithm  that  uses  non-dominated  sorting  and  crowding 
distance  to  differentiate  solutions  based  on  their  positions  in  the  multi-Chapter 2 
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objective  space.  It  is  very  efficient  in  its  fast  non-dominated  sorting 
capability to calculate Pareto optimal front and maintaining diversity. 
Figure 2.9 presents the essential mechanisms of evolution using NSGA-II. 
The initial generation of solutions are generated randomly and evaluated to 
get  values  of  their  objectives,  APNPV  and  p(NPV>0).  Then  a  selection 
procedure performs parental selection by randomly picking two solutions 
from the initial generation for comparison. The dominating solution from 
the two is selected as parent solution. The word “dominating” in this context 
indicates that one solution is strictly better than the other, i.e. it performs 
better in both objectives. If the two selected solutions are mutually non-
dominated,  the  algorithm  randomly  chooses  one  as  parent  solution.  For 
every  pair  of  parent  solutions,  the  crossover  and  mutation  operators  of 
NSGA-II are implemented, creating two offspring solutions, which are in 
part  the  same  with  their  parents.  These  offspring  solutions  are  then 
evaluated for performance measure before the algorithm selects another pair 
of parents for offspring production. This procedure goes on until the number 
of offspring is the same as the initial generation.  
NSGA-II combines the initial population and offspring population as one, 
and preforms non-dominated sorting, i.e. assign rank to every individual 
solution by the number of times it is dominated by other solutions. The best 
solutions are the ones with the least number of getting dominated by other 
solutions, which is also the one with the lowest number in its rank. The 
Pareto front is therefore comprised of the solutions that are not dominated 
by any other solutions, i.e. the solutions with Rank 0.  
Within  each  rank,  NSGA-II  assigns  crowding  distance  value  to  every 
solution.  The  crowding  distance  value  is  higher  when  solution  is  more 
isolated to other solutions in objective space. In this tool with 2 objectives, 
the crowding distance reaches the highest when solutions are at either end of 
the Pareto front.  
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The purpose of non-dominated sorting and crowding distance calculation is 
to provide support for environmental selection. The environmental selection 
procedure selects half of the combined population as the next generation 
based  on  their  ranks  and  crowding  distance  values.  This  procedure  first 
chooses the solutions with the lowest ranks. If the solutions of the same rank 
cannot be all included in the next generation, the environmental selection 
chooses the one with higher crowding distance value in order to maintain 
diversity across Pareto front.   
The selected solutions forms the next generation, which will go through the 
parental selection, offspring generation, evaluation, non-dominated sorting 
and  crowding  distance  calculation,  and  finally,  like  its  predecessor,  be 
replaced  by  environmental  selection.  The  algorithm  keeps  improving  the 
quality of the population so that the current Pareto front approximates the 
true Pareto front of the problem.  
2.4.4  Managing duplications 
Since the initial population is randomly generated and there is no guarantee 
that the crossover and mutation operators will not create an offspring that is 
identical  to  an  already  generated  solution,  it  is  possible  that  identical 
solutions exist in the same population. Additionally, the outcome of Monte 
Carlo simulations for the same solution are not exactly the same, making it 
possible for identical solutions within the same population being mutually 
non-dominated.  Therefore  there  can  be  scenario  that  after  running  the 
algorithm  for  several  generations,  the  tool  ends  up  with  a  Pareto  front 
consisting of the same solutions. This scenario is detrimental to the diversity 
of solutions this tool can provide and should be prevented.  
The  procedures  of  preventing  duplicated  solutions  within  population  is 
proposed and illustrated in Figure 2.10. These procedures not only prevents 
solution  duplications  within  population,  they  significantly  improves  the 
quality of evaluation results for solutions that are frequently generated.  
To eliminate identical solutions in population, the procedure keeps a record 
of the current solutions within the population and performs a duplication Chapter 2 
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check every time an offspring solution is generated. If it is a duplicated 
solution,  the  procedure  discards  the  offspring  and  re-runs  the  genetic 
operators  to  generate  a  new  offspring.  However,  this  is  not  enough  to 
address the duplication issue across generations. Certain solutions emerge 
again and again in different generations. The procedure does not discard the 
results of previous evaluations. It combines them with the new result to 
make it better.  
Table 2.5 presents the equations that can be used to calculate the combined 
results of evaluations. Based on the equations, the combined results can be 
calculated when the k-th evaluation is finished. The procedure only needs to 
record 3 variables: 1) the combined results of first (k-1)-th evaluations on 
the  average  positive  NPV,  2)  the  combined  results  of  first  (k-1)-th 
evaluations on the possibility of getting positive NPV, and 3) the number of 
existing evaluations, k-1.  
Table 2.5 Equations for updating the evaluation results based on current and 
previous evaluation results.  
Individual 
evaluation 
results 
Combined evaluation results 
𝐴 
= ﾠ
𝑆 
𝑁 
 
𝑝  = ﾠ
𝑁 
𝑁
 
   
𝐴 
= ﾠ
𝑆 
𝑁 
 
𝑝  = ﾠ
𝑁 
𝑁
  𝐴 ~  = ﾠ
𝐴  ∙ 𝑝  + 𝐴  ∙ 𝑝 
𝑝  ∙ 𝑁 + 𝑝  ∙ 𝑁
  𝑝 ~  = ﾠ
1
2
𝑝  + 𝑝   
𝐴 
= ﾠ
𝑆 
𝑁 
 
𝑝  = ﾠ
𝑁 
𝑁
  𝐴 ~  = ﾠ
2 ∙ 𝐴 ~  ∙ 𝑝 ~  + 𝐴  ∙ 𝑝 
2 ∙ 𝑝 ~  ∙ 𝑁 + 𝑝  ∙ 𝑁
  𝑝 ~  = ﾠ
1
3
2 ∙ 𝑝 ~  + 𝑝   
......  ......  ......  ...... 
𝐴 
= ﾠ
𝑆 
𝑁 
 
𝑝  = ﾠ
𝑁 
𝑁
 
𝐴 ~ 
= ﾠ
𝑘 − 1 ∙ 𝐴 ~     ∙ 𝑝 ~     + 𝐴  ∙ 𝑝 
𝑘 − 1 ∙ 𝑝 ~     ∙ 𝑁 + 𝑝  ∙ 𝑁
 
𝑝 ~ 
= ﾠ
1
𝑘
𝑘 − 1 ∙ 𝑝 ~     + 𝑝   
Ai – average positive NPV for the i-th evaluation; pi – possibility of getting positive 
NPV for the i-th evaluation; Si – sum of positive NPV for the i-th evaluation; Ni – 
number of positive NPV for the i-th evaluation; A1~i – average positive NPV for the 
first i-th evaluations; p1~i – possibility of getting positive NPV for the first i-th 
evaluations; N – number of Monte Carlo simulations. 
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2.5  DATA MANAGEMENT AND ANALYSIS 
In  order  to  effectively  collect  information  regarding  the  running  of 
optimization  algorithm  and  evaluation  of  solutions,  a  system  of  data 
reporting formats is designed and implemented. The information is initially 
recorded in Java using custom designed variables such as multi-dimensional 
arrays.  A  data  output  class  responsible  for  printing  results  into  text 
document is created to transfer information from those variables to outside 
text files.  
There are 3 major types of reports. The generational performance report 
presents the information collected during the running of the optimization 
algorithm  concerning  the  overall  performance  of  solutions  for  a  given 
population. These reports are placed in a generation-specific folder, along 
with  folders  for  solutions  and  reports  that  are  related  to  this  generation. 
Table 2.6 presents the data-reporting format of the generational performance 
report  with  sample  data.  The  purpose  of  this  report  is  to  record  the 
performance  information  about  a  solution  and  its  decision  variables. 
Analysis of optimization results from decision space and objective space is 
based on this report.  
Table 2.6 Format of generational performance report.  
Index  Rank  APNPV  p(NPV>0)  D1  D2  D3  D4  …… 
1  0  15324789  0.54  0  1  0  0  …… 
2  0  13365987  0.56  0  1  1  0  …… 
3  1  12568712  0.49  1  0  0  1  …… 
……  ……  ……  ……  …… 
Note: The report gives an index for each solution and presents the values of its 
objectives, the decision variables, and the non-dominated ranking. 
 
The cash flow report records the timing and origin of cash flows as well as 
their amounts for a given Monte Carlo simulation. The number of cash flow 
reports  within  a  solution  folder  equals  the  number  of  Monte  Carlo Chapter 2 
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simulations. Table 2.7 describes the format of cash flow report for a given 
Monte  Carlo  simulation.  A  multi-dimensional  array  was  designed  to 
accommodate  the  production  of  cash  flow  reports.  At  the  start  of  each 
Monte  Carlo  simulation,  this  array  is  initiated  with 𝑡 ∙ 𝑠 ∙ 3 dimensions 
where t represents  the  number  of  time  slices  for  dynamic  simulation,  s 
represents the number of stages in the drug development lifecycle, and 3 
represents the 3 types of activities this tool simulates, namely the clinical 
trial, manufacturing, and process development. In the end of this Monte 
Carlo simulation, a method is called in the data output class to transform the 
multi-dimensional data into a text file in Table 2.7 format.  
Table 2.7 Format of cash flow report. The report specifies the timing, origin, 
and stage for each cash flow. 
Time  Stage  Type  Value 
1  Phase I  Clinical trial  -35 
1  Phase I  Process development  -12 
1  Phase I  Manufacturing  -10 
2  Phase I  Clinical trial  -35 
2  Phase I  Process development  -12 
……  ……  ……  …… 
123  Phase III  Clinical trial  -72 
123  Phase III  Process development  -20 
123  Phase III  Manufacturing  -22 
……  ……  ……  …… 
 
Along  with  the  production  of  a  cash  flow  report,  an  activity  report  is 
generated for each Monte Carlo simulation. This report presents the actual 
timings of activities that are triggered and their states on completion. Table 
2.8 presents a sample activity report. The activity report provides critical 
information in the analysis of delays and project failures.  Chapter 2 
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Table 2.8 Format of activity report.  
Product  Stage  Type  Start time  End time   State 
Drug 1  Phase II  Clinical trial  289  372  Pass 
Drug 1  Phase III  Clinical trial  381  503  Fail 
Drug 1  Phase III  Manufacturing  360  380  Pass 
Drug 1  FDA  Process development  450  503  Interrupted 
……  ……  ……  ……  ……  …… 
Drug 2  Phase I  Clinical trial  112  173  Pass 
Drug 2  Phase II  Clinical trial  173  297  Pass 
Drug 2  Phase II  Manufacturing  158  170  Pass 
……  ……  ……  ……  ……  …… 
Note:  This  report  reveals  the  timing  of  triggered  activities  and  their  states  on 
completion of 1 Monte Carlo simulation. 
 
The  analysis  and  visualisation  of  data  in  the  above  report  formats  were 
accomplished  using  R  statistical  computing  language  with  ggplot2  data 
visualization package. The application can be found in Chapter 4 where the 
stochastic optimization tool is implemented. For results generated from drug 
development lifecycle cost model for cost evaluation purpose, Excel charts 
were created for data visualization in Chapters 3 and 5. 
2.6  CONCLUSION 
In this chapter, an activity-based drug development lifecycle cost model is 
proposed  to  capture  the  clinical  and  non-clinical  aspects  of 
biopharmaceutical portfolio development. The model is further developed 
with  Monte  Carlo  simulation  capability  and  dynamic  simulation 
mechanisms,  so  that  it  functions  as  an  evaluation  engine  for  support  of 
portfolio  management  decision-making  under  uncertainties  and  resource 
constraints.  This  evaluation  engine  produces  performance  appraisals  for 
portfolio management strategies in the form of NPV distributions.  Chapter 2 
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A multi-objective evolutionary algorithm NSGA-II is implemented in the 
stochastic optimization tool in order to efficiently search the decision space 
for  optimal  solutions.  A  binary  string  representation  of  portfolio 
management decisions is proposed for improved flexibility under changing 
portfolio  development  environment,  and  efficiency  in  genetic  operations 
during the running of the algorithm. The algorithm makes use of Pareto 
optimal approach in dealing with competing optimization objectives, i.e. the 
two  key  statistics  of  the  NPV  distribution,  the  average  positive  NPV 
(APNPV)  and  the  possibility  of  NPV  being  positive  (p(NPV>0)).  A 
procedure of managing solution duplications in population and in the course 
of optimization is introduced to maintain diversity and improve the quality 
of evaluations of frequently generated solutions.  
Various data reporting formats are introduced to facilitate the analysis of 
cost  evaluation  and  portfolio  management  optimization  results.  The  data 
management system takes advantage of the object-oriented, activity-based 
drug development cost model and stochastic optimization tool to produce 
reports that reflect the performance of generations, the cash flows and their 
respective origins, and the details of simulation of activities in their most 
explicit form. Excel charts and R statistical computing language are adopted 
in visualizing the results.  
Application of the drug development lifecycle cost model is presented in 
Chapter 3 to benchmark the cost of clinical and non-clinical activities for 
pharmaceutical and biopharmaceutical portfolio development. The model is 
further implemented in Chapter 5 with application to cost evaluation of cell 
therapy  portfolio  development.  The  stochastic  optimization  tool  for 
biopharmaceutical portfolio management decision support is implemented 
in  Chapter  4  with  custom  designed  candidate  pool  featuring  products  of 
various risk-reward characteristics. 
 CHAPTER 3   
COST OF MANUFACTURING AND PROCESS DEVELOPMENT 
IN BIOPHARMACEUTICAL NEW PRODUCT DEVELOPMENT 
3.1  INTRODUCTION 
The  pharmaceutical  industry  has  suffered  from  diminishing  R&D 
productivity and increasing R&D cost over the past decade (Scannell et al. 
2012). Typical portfolio return on investment often falls short in recovering 
the capitalized cost of development considering the complexity and risky 
nature  of  developing  new  therapeutics.  Compared  to  conventional 
pharmaceutical small molecule NMEs, biological products have a relatively 
higher  overall  success  rate.  Probabilities  of  FDA  approval  for 
investigational drugs in Phase I have been estimated to be 7.5% for NMEs 
and 14.6% for biologics (Hay et al. 2014). However, biological products are 
exposed  to  more  technical  difficulties  in  process  development  and 
manufacturing. Constant improvement of production methods requires the 
assessment  of  comparability  to  ensure  the  consistency  of  product 
characteristics that could affect safety, purity, efficacy, and stability of the 
finished product. Published studies have focused on evaluating the overall 
cost  of  R&D,  but  have  not  addressed  the  clinical  and  non-clinical  cost 
breakdowns  at  each  phase.  Using  the  model  proposed  in  the  previous 
chapter,  this  chapter  aims  at  benchmarking  the  costs  across  the  drug 
development lifecycle with special attention to the non-clinical activities, i.e. 
process development and manufacturing.  
Pre-clinical  and  clinical  trials  often  lie  on  the  critical  path  of 
biopharmaceutical  product  development,  with  support  from  process 
development  and  manufacturing.  Provisional  budget  allocations  and 
planning are required to safeguard the smooth running of R&D activities. 
Therefore  there  is  a  need  to  accurately  estimate  the  cost  of  process 
development  and  manufacturing  activities  for  different  attrition  rate 
scenarios. On the manufacturing level, published cost of goods analyses (e.g. 
Simiaria et al. (2012); Pollock et al. (2013) were drawn upon in this study to Chapter 3  
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determine and benchmark the manufacturing costs for the portfolio at each 
development stage for different attrition rate configurations. Estimations of 
personnel required in process development activities across developments 
stages are discussed and utilised as the basis for process development cost 
evaluation.  
A  pharmaceutical  product  development  pathway  model  is  introduced  to 
address  the  cost  of  non-clinical  activities  in  the  context  of  portfolio 
development targeting one market success. The general idea of capturing 
the “at-risk” nature of process development and manufacturing activities in 
portfolio development was developed and described in Chapter 2. In this 
chapter, the model is applied to a case study featuring industrially relevant 
drug development risk and cost scenarios. The model is further extended by 
an  analysis  of  cost  associated  with  the  “at-risk”  characteristics  of  non-
clinical activities in probabilistic scenarios.  
The remainder of this chapter is structured as follows. In Section 3.2 and 
Section 3.3 the model of drug development lifecycle, as well as its structure, 
is described. Section 3.4 explains the assumptions made for capturing the 
impact of delays in process development activities. The background to the 
case study is described in Section 3.5, which benchmarks attrition rates, 
costs,  and  timeline  of  milestones  for  single  product  development.  Cost 
evaluation  of  portfolio  development  and  the  analysis  of  economic 
implications of delay are discussed in Section 3.6.  
3.2  DRUG DEVELOPMENT LIFECYCLE DESCRIPTION 
The  biopharmaceutical  new  product  development  process  follows  an 
established pattern. An exploratory discovery research finds a new target of 
potential therapeutic use, then a number of molecules are developed and 
optimized,  and  the  best  one  among  them  is  selected  to  be  the  product 
candidate. This product candidate then goes through the pre-clinical trial 
phase  where  a  range  of  tests  are  run  both  in  vitro  and  in  animals  to 
characterize the likely safety and effectiveness of this molecule in treating Chapter 3  
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its  target  disease.  Upon  completion  of  the  pre-clinical  trial,  the  drug 
developer applies to regulatory authorities (e.g. FDA in USA) for approval 
to commence human clinical trials. Clinical trials are required to prove that 
the drug is safe and effective when administered to human patients. There 
are three major phases of clinical trials before the product gets approval for 
commercialization: Phase I tests the safety of the product in human, Phase II 
assesses its efficacy and Phase III aims at definitively assessing the efficacy 
and dosage in a large number of patients. Upon completion of clinical trials, 
the drug developer is required to gather all pre-clinical and clinical data 
generated during the process, along with details of the production process 
used  to  make  the  drug  and  cGMP  documentation,  and  submit  to  the 
regulatory authority for market entry approval. Once granted, the product 
developer can legally manufacture and sell the product.  
This study focuses on the development stages from pre-clinical to regulatory 
submission (i.e. the FDA review). The activities prior to the pre-clinical trial 
stage are not covered in this model because the costs generated at these 
stages are often shared with other compounds. Therefore the stages from 
discovery to lead optimization are omitted, leaving pre-clinical and clinical 
trial stages as the major cost drivers in this model.  
The development pathway described in this study assumed that only the pre-
clinical  and  clinical  trials  are  on  the  critical  path.  To  meet  the  timing 
requirement  of  activities  on  the  critical  path,  the  supporting  process 
development  and  manufacturing  activities  occur  off  the  critical  path  and 
hence are performed at risk before the go/no-go decision for the clinical trial 
is known. This model assumes for every development stage, the dependency 
exists  that  the  occurrence  of  activities  follows  the  path  from  process 
development to manufacturing, and then to the clinical trial. 
Manufacturing and process development activities are designed to meet the 
need of the clinical trials. In order to produce the products efficiently and at 
the  required  quality,  the  developer  must,  through  a  serious  of  process 
development activities, establish the manufacturing process and optimize it Chapter 3  
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to  meet  regulatory  requirements  as  well  as  reduce  cost.  Detailed  inter-
dependencies  between  clinical  trial,  manufacturing  and  process 
development activities are depicted in Figure 3.1. Pre-clinical trial materials 
are produced through an established cell line that provides products with 
low  titre  at  a  small  scale.  For  Phase  I  and  II  clinical  trials,  process 
development  focuses  on  process  scalability  and  improvement  of 
productivity,  since  more  material  is  required  for  clinical  trials.  Process 
development  for  Phase  III  and  regulatory  approval  mainly  focuses  on 
process characterization and validation. Initial process limit evaluation and 
validation studies commence at the early stage of process development prior 
to  Phase  III.  Major  characterization  and  validation  studies  run 
simultaneously with Phase III clinical trials in order to avoid causing any 
delay to submission to regulatory approval. Typical values of manufacturing 
scale and titre are incorporated in this model as 200L and 2.5g/L for pre-
clinical, 2000L and 3g/L for Phase I and II, and 5000L with 3g/L for Phase 
III and consistency batches required to validate the process. The Phase III 
scale of production was selected to match a typical commercial scale of 
production of 200kg/y for mAbs (Kelley 2009), which can be achieved with 
20  batches  at  the  5000L  scale  and  3  g/L  titre.  The  scale  and  titre  of 
manufacturing for commercialization is usually kept the same as Phase III, 
but this is not included in this study as it focuses on the costs of new product 
development.  
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3.3  DRUG DEVELOPMENT LIFECYCLE COST MODEL STRUCTURE 
A spreadsheet-based lifecycle cost model was built for biopharmaceutical 
drug  development  that  captured  the  costs,  durations,  risks  and 
interdependencies of both the clinical and non-clinical activities. The non-
clinical  activities  were  broken  down  into  process  development  and 
manufacturing. The term ‘process development’ was taken to include all 
bulk process and formulation development as well as the analytical effort 
for process characterisation and validation studies. The term ‘manufacturing’ 
was  taken  to  include  the  cost  of  manufacturing  batches  for  supply  of 
material  to  pre-clinical  and  clinical  trials  as  well  as  process 
validation/qualification consistency batches required for BLA submissions. 
These manufacturing costs were determined using a bioprocess economics 
model developed at UCL (Simaria et al. 2012).  
The tool establishes the product development pathway with the number of 
projects necessary to achieve a certain pre-set target. The evaluation of out-
of-pocket costs along the development pathway for a given year is based on 
two criteria: number of projects in the pipeline and total out-of pocket cost 
of a single project in that year.  
Figure  3.2  lists  the  required  input  parameters  for  the  model  and  the 
processed costs in pipeline and project-specific levels. On the pipeline level, 
the model requires the user to define their target in the form of desired 
number of successful market entries, and the cost of capital in the form of 
discount  rate.  Project  profitability  is  defined  as  the  sales  curve  of  the 
product that goes to market once the project is successful. Availability of 
technology platforms for process development activities is also considered 
on  the  project-specific  level  in  this  model.  For  pre-clinical  and  clinical 
studies, the phase transition probabilities (TP) are required to calculate the 
required number of projects to achieve the user’s desired target; duration & 
cost provides the basis for cost distribution in time; and demand of materials 
at clinical trial stages provides guidance on manufacturing cost evaluation. Chapter 3  
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Batch scale and batch cost are inputs provided at the manufacturing level to 
determine the number of production batches and the related cost. Finally, 
the cost and duration of process development activities are required, as well 
as the risk of delay in probabilistic form.  
The model then converts the inputs into outputs. At the beginning of the 
evaluation, the model builds up the timeline of the development pathway 
according to the inputs on duration of pre-clinical and clinical trials. Then 
based on their material requirements, the model generates manufacturing 
activities with the appropriate number of production batches. The timings of 
manufacturing activities are set to meet the clinical material requirement. 
The process development activities are planned to provide technical support 
for manufacturing at various stages. After the model plans all the clinical 
and  non-clinical  activities  for  developing  a  single  product,  it  starts  to 
calculate, based on the attrition rates of the development cycle, how many 
products the user needs at each step to achieve the target number of  market 
successes. With the number of products being developed and the cost of 
developing each one determined, the total cost is evaluated.  
The  outputs  at  the  pipeline  level  provide  the  user  with  information 
concerning  how  much  it  costs  to  achieve  their  target  in  terms  of  total 
capitalized cost. Figures on the out-of-pocket costs for each year are also 
presented as outputs and they serve a more practical purpose for budget 
planning.  More  specifically,  the  cost  breakdown  of  clinical  trials, 
manufacturing and process development is also available for more detailed 
budget planning. On the project level, the model produces the costs of each 
individual project and the time of proposed market entry, which gives the 
decision maker an indication of the amount of investment and the time to 
market. In addition, the model also provides valuations of a single project 
by development stage, which could be more useful to parties involved in 
product licensing deals. 
 Chapter 3  
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Figure 3.2 Tool structure with input and output parameters for the model.  
The flow of information is from the left side of inputs, through the drug 
development lifecycle cost model in the middle for calculations, to the outputs of 
results in various formats on the right side.  
 
3.4  ADDRESSING THE RISK OF DELAY 
This tool is capable of analysing cost when the risk of development delay is 
considered. The starting and end times of development activities are results 
of  scheduling  without  leaving  margin  for  possible  delays.  Therefore 
whenever a delay occurs during a certain development activity, the timing 
of the subsequent dependent activities are affected and eventually delays the 
product’s marketing approval. From the out-of-pocket cost perspective, this 
model  assumes  that  the  rate  of  spending  is  constant  over  time  for  each 
activity,  so  the  delayed  activities  cost  more.  From  the  capitalized  cost 
perspective,  it  costs  more  when  the  spending  period  is  prolonged.  More 
importantly, a delay in market entry could be detrimental to a product’s 
sales, causing it to lose value.  
Delays of development activities are modelled in a probabilistic fashion in 
this  model.  Every  activity  has  a  probability  of  delay  and  two  possible 
outcomes: normal and delayed. In this way, a binary tree, given the chance Chapter 3  
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and impact of delay for all activities, can be used to describe every possible 
scenario of biopharmaceutical new product development pathway when risk 
of  delay  is  considered.  The  tool  evaluates  the  cost  structure  for  every 
possible  scenario  and  calculates  the  expected  values  of  cost  using  the 
probabilities of these scenarios. 
3.5  CASE STUDY SETUP 
The purpose of this set-up is to simulate the process of biopharmaceutical 
new  product  development  pathway  so  that  the  process  development  and 
manufacturing costs across the biopharmaceutical drug development cycle 
can be estimated. Hence it was critical to have representative input values 
for the key risks, costs and timelines in the development cycle. The key 
assumptions  were  derived  through  a  detailed  review  and  comparison  of 
various sources of industrial cost analysis data so as to derive representative 
figures  as  inputs  for  this  study.  An  established  manufacturing  process 
economics  model  (Simaria  et  al.  2012)  was  utilized  to  derive  the 
manufacturing costs at different titres and scales of production.  
3.5.1  Development risk profiles 
The clinical failure rates at each phase in the drug development process play 
key roles in cost evaluation. In this model, the risk of clinical failure is 
characterized  by  the  phase  transition  probabilities  (TPs)  of  projects. 
Published statistical data were drawn upon when building up the case study 
scenarios, as presented in Table 3.1. The first scenario features the most 
optimistic  situation  where  the  highest  phase  transition  probabilities 
published for each stage were used (DiMasi & Grabowski 2007; Bogdan & 
Villiger 2010; Paul et al. 2010). Scenario 2 used an industrial average for 
the  phase transition probabilities derived from Paul et al. (2010)  to provide 
a  more  balanced  evaluation.  Scenario  3  represented  a  more  pessimistic 
outlook. It used the industrial average phase transition probabilities from 
pre-clinical to Phase II stage, but addressed the possibility that for some Chapter 3  
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therapeutic  areas  such  as  Alzheimer’s  disease,  the  phase  transition 
probability of Phase III could be extremely low due to the novelty of the 
drug targets being pursued and to the lack of animal models with a strong 
capacity to predict human efficacy (Pauls et al. 2010). The likelihood of 
approval  (LOA)  and  the  required  numbers  of  products  for  one  market 
success  from  Phase  I  to  market  approval  for  all  3  scenarios  are  also 
presented. 
Table  3.1  Risk  profiles  of  new  biopharmaceutical  product  development 
represented by phase transition probabilities. 
Phases  PC  I  II  III  FDA   PhI LOA
a  PhI N
b 
Optimistic   70%  85%  55%  70%  91%  29.8%  3.4 
Average  69%  54%  34%  70%  91%  11.7%  8.6 
Pessimistic   69%  54%  34%  21%  91%  3.5%  28.5 
a LOA  = likelihood of approval from Phase I. 
b N= number of Phase I products required for one market success. 
 
3.5.2  Cost estimations for developing a single product 
Cost of process development 
The  definitions  of  process  development  and  its  associated  costs  in 
biopharmaceutical  product  development  vary  between  sources  and 
orgnaisations.  In  this  model,  process  development  was  defined  as  the 
activity  that  establishes  and  optimizes  the  manufacturing  of 
biopharmaceutical  product  for  clinical  and  commercial  purposes,  and 
provides  knowledge  for  regulatory  compliance.  The  cost  associated  with 
process development was therefore distributed across strain development, 
process synthesis, design, optimization, characterization, validation, and the 
related analytical development activities. The cost of manufacturing clinical 
material was not included in the cost of process development, regardless of 
its  scale.  The  cost  of  manufacturing  consistency  batches  for  process 
validation purpose was included in the cost of process development, only if Chapter 3  
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the product was not used in clinical trials or commercial sales. Otherwise it 
was considered as a cost of manufacturing. This case study assumed that the 
material produced from consistency batches would be used for Phase III 
clinical trials, therefore the related manufacturing cost was not included in 
process development.  
The estimation of process development costs adopted a full-time equivalent 
or FTE year based approach. This approach first reviewed the necessary 
tasks  for  each  step  of  process  development  in  biopharmaceutical  new 
product  development,  then  derived  the  workload  required  to  fulfil  these 
tasks in terms of FTE year, and applied a fixed cost incurred to the company 
in  every  unit  of  FTE  year  to  account  for  the  actual  cost  of  process 
development.  
Table  3.2  contains  the  estimated  FTE  required  for  major  process 
development activities in this model. The calculation of FTE was based on 
the number of personnel and their relative involvement in performing their 
function compared to a full-time employee. As an example of calculation, 
an  employee  working  2  hours  per  working  day  on  this  project  only 
accounted for 0.25 FTE. This principle applies to all the personnel working 
in regulatory support and QC/QA functions that are not dedicated to any 
specific project.  
The cost of the process development activity was determined based on the 
total workload it required. On average, for every unit of FTE year workload, 
the overheaded cost incurred to the company was assumed to be $250,000, 
including not only the FTE salary, but also all accompanying cost in process 
development.  
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Table 3.2 Estimated personnel and cost for process development activities in 
new  biopharmaceutical  product  development  (J.  Coffman,  Boehringer 
Ingelheim, personal communication).  
Stages  PC/Phase I  Phase II  Phase III  FDA (PD)  FDA (Comm) 
FTEs           
Project manager  1  1  2  2  0 
Process scientists  3  6  10  12  0 
Tech-transfer  1  2  4  4  0 
Regulatory support  0.5  1  2  10  0 
QC/QA  0.5  2  2  4  20 
Site support  0  0  0  0  20 
Total FTE  6  12  20  32  40 
Duration (year)  1  0.5  2  1.5  1.5 
FTE year  6  6  40  48  60 
Cost ($ million)  1.5  1.5  10  12  15 
Note: The process development activity in FDA review stage is divided into 2 
separate parts: FDA (PD), with the original process development team working towards 
submission, and FDA (Comm) with a team of QC/QA and site support personnel working 
on commercial manufacturing. 
 
For  every  step  of  process  development,  it  was  assumed  that  a  project 
manager was required to work full time in order to coordinate the work of 
the team and communicate with other relevant divisions of the company that 
facilitate  the  on-going  process  development.  For  the  early  stages  of 
development,  one  project  manager  was  assumed  to  be  sufficient  for  the 
relatively small process development team, whereas for the late stages of 
development, the size of the team increases significantly so that one extra 
project manager was required. Process scientists are needed for upstream 
and downstream process establishment, optimization, characterization, and 
validation. Hence they are needed from the start of the development life 
cycle.  Requirement  of  personnel  in  charge  of  tech-transfer  to  pilot  and 
large-scale manufacturing increases as the scale of manufacturing increases. Chapter 3  
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The FTE required at a scale of 200L, 2000L, and 5000L was set as 1, 2, and 
4, respectively. The regulatory support required at pre-clinical and clinical 
stages is much less than that required at the FDA review stage. The QC/QA 
personnel works on developing analytical assays for process development, 
but they are normally working for multiple projects. The FTE figures for 
QC/QA  were  adjusted  by  the  number  of  projects  that  one  specialist  can 
simultaneously  handle  and  the  number  of  specialists  required  for  each 
process  development  step.  The  process  development  activities  at  FDA 
review  stage  were  divided  into  two  areas,  with  the  original  process 
development group working on the final process characterization, validation, 
and  documentation  for  submission,  while  another  group  consisted  of 
QC/QA and site support personnel working on preparations for commercial 
manufacturing.  Given  the  definition  of  process  development  described 
earlier, the preparation of commercial manufacturing was considered as part 
of  process  development,  and  hence  it  was  important  to  include  the  cost 
incurred.   
Cost of manufacturing 
The  cost  of  manufacturing  in  pre-clinical  and  clinical  development  was 
calculated using an established UCL process economics model (Simaria et 
al. 2012) with inputs on scale of fermentation, titre, and clinical material 
demand. Estimation of material demand in clinical trials was based on the 
number  of  patients  participating  in  each  stage.  Table  3.3  presents  the 
assumptions for patient numbers for clinical trials. With the assumptions 
that the average patient body weight is 86kg and the approximate dosage per 
body weight is 7mg/kg, one dose of treatment requires 0.602g material. For 
Phase I, 1 dose per patient is sufficient to test product safety. For Phase II 
and III, the number of doses administered per patient is related to the length 
of test period and the frequency of administration. This case study assumed 
the frequency of taking 1 dose every 2 weeks and the average lengths of 
clinical test for Phase II and III were 0.5 and 1 year, respectively. Typically, 
drug  developers  produce  more  product  than  needed  for  clinical  trials  to Chapter 3  
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support non-clinical uses related to quality analysis and testing as well as 
contingency inventory(e.g. in case of change in dosage or product loss). The 
ratio of overproduction applied to early phases is 250% and for Phase III is 
125%, as the uncertainty of manufacturing decreases. The adjusted demand 
that  takes  into  account  the  overproduction  was  therefore  considered  the 
target  demand  for  the  process  economics  model  to  calculate  the 
manufacturing cost. The target demand of pre-clinical stage material was 
assumed 0.5 kg, according to industrial opinion (J. Coffmann, Boehringer 
Ingelheim, personal communication).  
Table 3.3 Estimation of bulk product demand in clinical trials. 
Stage 
Patient 
number
a 
Duration 
(year) 
Dose  Demand 
Over 
production 
Adjusted 
demand 
Phase I  40  n/a  40  24 g 
250%  4 kg 
Phase II  200  0.5  2600  1.6 kg 
Phase III  2000  1  52000  31.3 kg  125%  40 kg 
a  The  estimated  patient  numbers  are  from  previous  modelling  research 
(Simaria et al. 2012) 
The adjusted demands for pre-clinical and clinical trials were then fed into 
the  process  economics  model  for  calculation  of  the  manufacturing  cost. 
Assumptions  related  to  the  fermentation  scale  and  titre  are  presented  in 
Table 3.4. At the pre-clinical stage, the manufacturing process is established 
at a pilot scale of 200L and the titre 2.5g/L. At Phase I and II, 2000L cGMP 
facility  with  3g/L  titre  was  assumed  to  be  the  standard  set  up  of 
manufacturing. The fermentation scale was further increased to 5000L and 
titre maintained at 3g/L at Phase III, as more material was required at this 
stage and this process scale would be locked for commercialization. The 
improvement of manufacturing scale and titre was considered the result of 
process development.  
The process economics model determined the cost per batch and this was 
split into two categories: direct and indirect cost. The direct cost accounts Chapter 3  
 
  89 
for the use of labor, consumables, chemical reagents, and direct utilities 
during the manufacturing process. The indirect cost accounts for the cost of 
running  the  facility,  including  maintenance,  general  utilities,  and  capital 
charges. The indirect cost per batch was determined by spreading the annual 
indirect cost over a representative number of annual batches (20 in the pre-
clinical facility) and 10 in the clinical facilities).  
Table 3.4 Estimation of batch cost and number of batches required in new 
product development.  
  Model inputs 
Cost per batch 
($ million) 
 
 
Scale 
(L) 
Titre 
(g/L) 
Demand 
(kg) 
Direct  Indirect  Total 
Batch 
required 
PC  200  2.5  0.5  0.25  0.12  0.37  3 
Ph I & II  2000  3  4  0.56  0.71  1.27  2 
Ph III  5000  3  40  0.91  0.89  1.8  5
a 
The direct cost per batch includes cost from labour, consumables, chemical 
reagents, and direct utilities. For the labour cost, the model assumes 4 operators 
working in the pre-clinical pilot scale facility and 9 operators working in larger 
scale facilities. The indirect cost accounts for the cost of facility maintenance, 
general utilities, and capital charges. These items are linked to the cost of fixed 
capital investment of building the facility. The Lang factor of facility supplying for 
pre-clinical, Phase I &II, and Phase III is 4.5, 6, 6 respectively. Using 4.5 as Lang 
factor for pre-clinical facility because GMP is not required. The indirect cost 
generated by having the facility is calculated as an annual average. The indirect 
cost per batch is calculated by spreading the annual indirect cost evenly to the 
number of batches produced. The number of batches produced every year at pre-
clinical facility is 20; at clinical facility is 10.  
a 3 of theses Phase III batches are also used for consistency batches.  
 
Cost of clinical trials 
Clinical  trials  contribute  most  to  the  total  cost  of  developing 
biopharmaceutical  new  products.  Various  sources  have  published  stage 
costs of developing new products, which can be considered as the total costs 
of clinical trials, manufacturing, and process development. Therefore, this 
model derived the costs of clinical trials using published total cost excluding Chapter 3  
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the  non-clinical  components,  namely  the  process  development  and 
manufacturing costs described in the previous sections. As shown in Table 
3.5, the cost of clinical trials were derived by deducting the non-clinical 
costs from published total stage costs. For pre-clinical trials, the $7 million 
total stage cost from Bogdan & Villiger (2010) was adopted as DiMasi & 
Grabowski’s (2007) figure includes costs from previous stages. For FDA 
review stage cost, the published figure refers to pharmaceutical industry in 
general, not specific to biopharmaceuticals. Hence the cost of clinical trial 
only accounts for the fees required for BLA license.  
Table 3.5 Assumption on cost structures and comparison to published total 
stage costs for biopharmaceutical new product development.  
Cost ($ million)  Pre-clinical  Phase I  Phase II  Phase III  FDA 
Published total  
DiMasi & Grabowski 2007 
Paul et al. 2010 
 
59.88
 
5 
 
32.28 
15 
 
37.69 
40 
 
96.09 
150 
 
N/A
 
40 
Model assumptions 
Process development 
 
1.5 
 
0 
 
1.5 
 
10 
 
27 
Manufacturing  1.11  1.27  1.27  9
c  0 
Clinical trials 
(DiMasi) 
Clinical trials (Paul) 
4.4
a 
4.4 
31 
13.7 
35 
37.2 
77 
131 
3
b 
3 
a Cost of pre-clinical clinical trial is calculated based on $7 million stage cost 
(Bogdan & Villiger 2010).  
b $3 million is license cost only at FDA review stage. 
c This cost includes the cost to produce consistency batches. 
 
3.5.3  Development timeline and milestones 
To establish the new product development pathway, durations of activities 
and  their  dependencies  are  required.  Table  3.6  presents  the  durations  of 
activities  from  3  categories,  based  on  published  sources  and  industrial 
opinion. Zero duration of activities indicates that there is no activity from Chapter 3  
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the category at the given development stage. Therefore from Table 3.6 it can 
be seen that it was assumed there would be no process development for the 
Phase I stage as the process would not be changed typically between animal 
and the first-in-human trials, and no manufacturing activity for clinical trials 
at FDA review stage.  
Table 3.6 Duration of activities.  
Stage  PC  I  II  III  FDA 
Clinical trial duration (year)  1  1.6  2.4  2.7  1.5 
Process development duration 
(year) 
1  0  0.5  2  1.5 
Manufacturing duration (week)  6  5  5  13  0 
Note: Durations of clinical trials are from DiMasi & Grabowski (2007); duration of 
pre-clinical is from Paul et al. (2010); durations of process development and 
manufacturing are from industrial expertise (J. Coffman, Boehringer Ingelheim, 
personal communication), given the task for process development and number of 
production batches. 
 
In  this  model,  the  dependencies  between  these  3  categories  of  activities 
follow the rationale that 1) clinical trials, including pre-clinical tests, require 
clinical material supply which is the result of manufacturing activities; 2) 
manufacturing  is  supported  by  process  development.  So  for  any  given 
development stage, the order of activities is from process development to 
manufacturing, and then to clinical trials, unless there is no such activity at 
that stage. Due to this set up, some activities have to run at risk of project 
failure, as depicted in Figure 3.3. This includes the manufacturing of Phase I 
and II materials, and the process development for Phase II. For Phase III, 
only  part  of  the  process  development  activity  is  running  at  risk  because 
there is a preparation stage between the decision to continue and the actual 
clinical material demand. 
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3.6  RESULTS AND DISCUSSION 
A  detailed  analysis  is  presented  of  the  process  development  and 
manufacturing costs across the biopharmaceutical drug development cycle. 
The non-clinical budgets needed at each phase of development to ensure a 
market success each year were estimated. The impact of different clinical 
success rate profiles on the process development and manufacturing costs at 
each stage was investigated.  
3.6.1  Cost evaluations 
The initial results were generated by the model to benchmark cost, time and 
number of projects that would finally achieve one market success at the end 
of  development  pathway.  Under  the  given  case  study  set-up,  the  model 
constructed a full R&D portfolio with the number of projects required to 
achieve the desired target. The development pathway was established for 
each project and its corresponding manufacturing and process development 
activities  scheduled.  The  costs  along  the  development  timeline  are 
calculated for 3 scenarios.  
The total out-of-pocket cost to have one market success was calculated by 
the  model  to  be  $442  million,  $748  million,  and  $2417  million  for  3 
scenarios featuring low, average, and high risk of failure in the process. The 
percentage of a biologics company’s R&D out-of-pocket costs that needs to 
be  allocated  to  process  development  and  manufacturing  for  each 
biopharmaceutical launched was found to vary between 16.8-21% for Phase 
I  to  launch  success  rates  of  3.5  -  29.5%..  This  translated  into  total 
manufacturing  out-of-pocket  costs  for  the  portfolios  under  the  three  risk 
profiles  of  $30M,  $54M,  and  $182M  respectively  and  total  process 
development out-of-pocket costs of $62M, $88M, and $225M respectively. 
Figure 3.4 indicates the breakdown of the portfolio costs for the industrial 
average  scenario.  The  results  indicate  how  process  development  and 
manufacturing budgets should be distributed across the various phases. In Chapter 3  
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Figure  3.4,  in  terms  of  non-clinical  activities,  the  Phase  III  process 
development and manufacturing consumes the highest proportion of out-of-
pocket funds per success ($41M in the industrial average case), followed by 
the  non-clinical  cost  for  preclinical  stage  ($32M),  process 
validation/characterization  in  the  FDA  review  stage  ($30M),  Phase  II 
($24M), and then Phase I ($16M). 
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The  distribution  of  process  development  and  manufacturing  cost  across 
development  stages  differs  as  the  risk  scenario  changes.  Defining  early 
stage as from pre-clinical to Phase II and late stage as from Phase III to 
BLA submission, all early stage process development and manufacturing 
are  running  at  risk.  Therefore  costs  of  process  development  and 
manufacturing  from  early  stage  increases  faster  than  late  stage  as  the 
development risk increases. 
Table 3.7 Process development and manufacturing cost expected to ensure 1 
market success in industrial scenarios featuring low, average, and high risk of 
failure.  
Risk profiles  Optimistic (~29.8%)  Average (~11.7)  Pessimistic (~3.5%) 
Early  28  72  239 
Late  65  71  167 
Note: Costs of process development and manufacturing are aggregated by their 
associated development stages. Development stages from pre-clinical to Phase II 
are defined as early stage and Phase III to FDA review are defined as late stage. All 
cost figures are in $ millions. 
 
The  impact  of  lower  success  rates  and  the  resulting  higher  numbers  of 
candidates at each phase on capacity requirement must also be considered in 
order to ensure sufficient process development labs are available as well as 
pilot and large scale GMP manufacturing facilities.  
A complete collection of cost evaluations of new drug development under 3 
risk assumptions with DiMasi and Paul’s publications as major sources for 
phase costs is presented in Figure 3.5 and Figure 3.6. 
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Figure 3.5 Cost evaluation of new drug development under 3 risk assumptions 
based on DiMasi’s phase cost. Chapter 3  
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Figure 3.6 Cost evaluation of new drug development under 3 risk assumptions 
based on Paul’s phase cost. Chapter 3  
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The total costs for each phase are summarized and their proportion to the 
total  out-of-pocket  cost  calculated.  In  Figure  3.7,  the  division  of  new 
product  development  R&D  spending  is  presented  for  3  risk  profiles, 
showing  that  Phase  I  is  the  major  cost  driver  in  biopharmaceutical  new 
product portfolio development (37%) while the spending on FDA review 
stage  is  only  4.4%  of  the  total  cost.  By  evaluating  the  phase-wise  cost 
composition for projects of low and high risk profiles, the model outputs 
show that there is a bigger market for early stage development projects in 
high-risk scenarios than in low risk scenarios.  
 
Figure 3.7 Cost distributions across development stages.  
The cost distributions across stages are presented under 3 scenarios featuring 
average, low, and high risk of development failure. The pie chart within this figure 
emphasizes the industrial average cost distribution for pursuing 1 market 
successful product. These costs are out-of-pocket costs including the cost spent on 
failed projects. 
 
For manufacturing and process development costs, the model summarizes 
their significance by development stages for 3 scenarios. Figure 3.8 shows 
the process development and manufacturing cost distribution across pipeline Chapter 3  
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development  stages.  Overall,  the  variation  of  success  rate  from  3.5%  to 
~12% or to 30% makes a 2.8 or 4.4 times reduction in manufacturing and 
process  development  costs.  In  the  industrial  average  scenario,  for  each 
market  success,  the  biopharmaceutical  drug  developer  needs  to  allocate 
$72M of budget to process development and manufacturing activities from 
pre-clinical  to  Phase  II  stage,  and  $71M  from  Phase  III  to  the  BLA 
submission  stage.  For  the  low  risk  (success  rate  29.5%)  and  high  risk 
(success rate 3.5%) scenarios, these values are $28~239M for early phases 
and $65~167M for late phases. From low risk to high risk, the investment 
into manufacturing increases faster than process development. This is due to 
the assumption that there are more at risk investments into manufacturing 
than  process  development,  therefore  increasing  the  number  of  projects 
required  causes  more  increase  in  manufacturing  cost.  For  the  industrial 
average, the cost of manufacturing should be approximately 62% of the cost 
of process development. At the low risk scenario, the drug developer should 
be focusing on the late stage manufacturing and process development, as 
they are the majority of investment. At the high risk scenario, the cost ratio 
of 1) early stage process development, 2) late stage process development, 3) 
early stage manufacturing, and 4) late stage manufacturing is approximately 
1:1.15:0.95:0.6.  For  company  with  large  development  portfolio,  cost 
reduction  methods  such  as  streamlined  technology  platform  for  process 
development and manufacturing at early stage are useful.  Chapter 3  
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Figure 3.8 Process development and manufacturing cost distribution across 
development stages.  
The process development and manufacturing cost distributions across stages are 
presented under 3 scenarios featuring average, low, and high risk of development 
failure. These costs are out-of-pocket costs including the cost spent on failed 
products. 
 
3.6.2  At-risk sensitivity analysis 
One of the key decisions in biopharmaceutical new product development 
process is the planning of Phase III process development so that it meets the 
supply requirement of the clinical trials. Considering the high cost of Phase 
III  process  development,  the  decision  maker  faces  the  trade-off  between 
higher  cost  and  potential  delay.  The  zero  delay  decision  would  place  a 
significant portion of process development activity before Phase III clinical 
trial  starts,  which  could  lead  to  maximum  investment  lost  if  the  project 
failed at Phase II.  
This analysis used the standard durations from base case as the mean value 
of  activities.  The  uncertainties  were  introduced  by  applying  normal 
distributions to the durations of activities. For Phase III stage, the activities Chapter 3  
 
  102 
and time points of concern are the Phase III process development activity, 
Phase III clinical trial preparation period, and the time point of Phase II end 
and Phase III starting. A 4 months standard deviation was applied to the 24 
months duration of Phase III process development activity, indicating that 
there was nearly a 95% chance that the duration was within 16-32 months 
range (2 times the standard deviation from the mean value). By defining the 
cost invested to the process development activities on the failed projects as 
“risk  cost”,  this  cost-risk  trade-off  is  presented  in  Figure  3.9  for  a 
development portfolio of average development risk.  
The  likelihood  of  causing  delay  in  critical  path  can  be  reduced  by 
prolonging the duration of process development running at risk, i.e. starting 
the process development activity early. However, the effect diminishes as 
the risk reduces, and it is almost impossible to remove any chance of delay. 
Therefore in this analysis, a 10% likelihood of delay is introduced as the 
maximum tolerance of risk from the decision maker. To achieve this level 
of  safety,  the  process  development  activity  should  start  at  14.2  months 
ahead of the Phase III decision, which implies that potentially $18 million 
investment is made at risk and could be lost if the projects failed to proceed 
to Phase III. The risk cost is affected by the portfolio risk profile. A high-
risk profile increases the risk cost of reducing clinical trial delays.  
The  above  analysis  is  based  on  the  assumption  that  the  clinical  trial 
preparation time is certain, which is not in some cases. Applying a 3 months 
standard deviation to the length of Phase III clinical trial preparation time 
will increase the difficulty of reducing the risk of delay. To achieve the 
same level of risk tolerance, the risk duration should be increased to 15.5 
months which translates into a risk cost of $19.7 million. On the other hand, 
if the level of uncertainty reduces and the standard deviation of process 
development  length  is  3  month,  12.9  months  of  risk  duration  and  $16.4 
million risk cost would be adequate in achieving the target tolerance.  
If the company developed a technology that reduces the expected length of 
process development, it will reduce the risk cost significantly. For example, Chapter 3  
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with  the  industrial  average  risk  profile,  if  this  technology  is  capable  of 
reducing the expected length of process development by 6 months and the 
standard deviation by 1 months, a 25% reduction, the resulting risk cost 
required to achieve the same level of safety would be $8.9 million, and risk 
duration 7 months. The value of this technology is therefore the reduction of 
risk cost for approximately $9 million.  
 
Figure  3.9  Trade-off  between  at  risk  investment  into  Phase  III  process 
development and having delay to the product development process.  
The Phase III process development activities are partially running at risk in order to 
avoid causing delays in supplying material to Phase III clinical trials. Due to the 
uncertainty within the duration of the activity itself that is quantified as a Gaussian 
distribution here, there is the possibility of causing delay to the critical path of 
development. Starting the process development at risk earlier than the expected 
required timing could mitigate the likelihood of delay, however this will increase 
the investment at risk that is defined as the cost to the projects that are going to fail. 
This analysis applied 3 levels of uncertainties to the 3 scenarios of risk profile. The 
low level of uncertainty assumes all information to be certain, apart from the length 
of the process development subjected to a 3 months standard deviation to the 
expected 24 months length (PD=3, CT=0). The medium level of uncertainty 
increases the standard deviation of process development length to 4 months (PD=4, 
CT=0). The high level of uncertainty maintains the variance of process 
development length while assuming the period between Phase III decision and the 
actual demand to be uncertain and subjected to a 3 months standard deviation to 
the expected 18 months length (PD=4, CT=3). A maximum tolerance of 10% 
likelihood of delay is applied to various levels of uncertainties and risk profiles 
yielding the timing and cost required to achieve the level of safety.  
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3.7  CONCLUSION 
This chapter benchmarks the cost to develop and manufacture therapeutic 
biologics  across  the  drug  development  lifecycle,  emphasizing  the  cost 
distributions across both development stages and clinical and non-clinical 
activities. This was achieved with the biopharmaceutical drug development 
lifecycle model described in Chapter 2 that captured the costs, durations, 
risks and interdependencies of both the clinical and non-clinical activities. 
The non-clinical activities were broken down into process development and 
manufacturing. A detailed analysis is presented of the process development 
and  manufacturing  costs  across  the  biopharmaceutical  drug  development 
cycle on a single drug and portfolio basis. The non-clinical budgets needed 
at each phase of development to ensure a market success each year were 
estimated for three representative clinical risk profiles and two industrially 
relevant average stage cost alternatives.  The costs of process development 
and manufacturing activities at each stage and their proportions of the total 
cost were further investigated in a sensitivity analysis with changing risk 
and cost scenarios. The economic implication of efforts that minimize the 
risk of delay was explored through a probabilistic approach that applied 
uncertainties  to  the  durations  of  activities.  The  analysis  lays  down  the 
foundation for portfolio management optimization based on cost and risk 
related parameters, which is discussed in the next chapter.  
 
 CHAPTER 4   
STOCHASTIC OPTIMIZATION OF BIOPHARMACEUTICAL 
PORTFOLIO DEVELOPMENT DECISION-MAKING UNDER 
RESOURCE CONSTRAINTS AND UNCERTAINTIES 
4.1  INTRODUCTION 
In  Chapter  3,  the  cost  evaluation  of  biopharmaceutical  portfolio 
development was presented and the benchmark of cost distributions across 
development  stages  and  activity  categories  were  captured  using  a  drug 
development  lifecycle  cost  model.  In  this  chapter,  the  stochastic 
optimization  tool  is  implemented  to  assist  biopharmaceutical  portfolio 
management decision-making with a diversified product candidate pool.  
The  pharmaceutical  industry  has  suffered  from  diminishing  R&D 
productivity  and  increasing  R&D  cost  over  the  past  decade.  Portfolio 
management decisions are critical to pipeline development especially when 
exposed  to  outside  competition  such  as  follow-on  drugs.  Studies  have 
indicated that most of the follow-on drugs had already started clinical trials 
before  the  approval  of  the  corresponding  original  (first-in-class)  drugs 
(DiMasi & Faden 2010). Published studies on R&D portfolio management 
have  focused  on  decisions  related  to  candidate  selection  and  capacity 
sourcing, but have not concentrated on the issues of budget and capacity 
planning in different stages of development that can impact the progression 
between  development  milestones.  By  implementing  the  stochastic 
optimization tool described in Chapter 2, the drug portfolio developer is 
able to obtain more information regarding the actual budget and capacity 
required in various development stages, and gains insight into the cash flow 
characteristics  of  the  optimal  solutions  produced  by  the  algorithm. 
Therefore better outcomes can be achieved from the execution of optimal 
portfolio management strategies.  
The case study proposed in this chapter investigates scenarios where the 
product candidates in the portfolio are all novel in-house candidates starting Chapter 4  
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at the pre-clinical stage as well as scenarios where the product candidates 
available for selection in the starting portfolio include products at different 
stages of development, which can be the case for some drug development 
portfolios. Choosing a product candidate that is in a later development stage 
can be beneficial as it is more likely to reach the market and the remaining 
cost of development is less than that for a candidate that is at an earlier 
development stage. However, the drug portfolio developer may not have 
direct  access  to  such  products  that  are  owned  by  other  organizations. 
Acquiring these products normally involves a large amount of upfront cost, 
which can be associated to the cost spent to bring the product to the current 
stage. In this chapter, the impact of upfront cost and its interaction with 
budget constraints is presented and analysed under the scenario that product 
candidates are at different stages. 
The  remainder  of  this  chapter  is  structured  as  follows.  Section  4.2 
introduces  the  tool  implemented  in  this  chapter.  The  case  study  input 
parameters  to  this  tool  are  presented  in  Section  4.3  as  well  as  the 
configurations for resources constraints and algorithm running parameters. 
In Section 4.4, the optimization of biopharmaceutical portfolio management 
is presented under budget and capacity constraints, and the impact on the  
cash  flow  for  clinical  and  non-clinical  activities  is  presented.  Finally, 
Section 4.5 extends the analysis to a more diversified candidate pool with 
options  to  acquire  outside  products  that  are  more  advanced  in  the  drug 
development process.  
4.2  TOOL DESCRIPTION 
The stochastic optimization tool implemented in this chapter was originally 
proposed in Chapter 2. The tool is comprised of 1) an evaluation engine 
capable of performing Monte Carlo simulation and dynamic simulation for 
integration of resource constraints with drug development uncertainties; 2) 
an multi-objective evolutionary algorithm for optimizing drug development 
portfolio  management  decisions  based  on  the  results  produced  by  the Chapter 4  
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evaluation engine; and 3) a data management system to collect information 
for further analysis during the running of the tool.  
For  the  purpose  of  the  analysis  presented  in  this  chapter,  the  tool  was 
operated  with  its  full  functionality,  with  all  the  features  of  the  3  key 
components turned on. However, crucial inputs regarding the development 
characteristics  of  product  candidates,  the  configuration  of  resource 
constraints,  and  the  set  up  of  running  parameters  were  still  required  for 
formulating the case study. These are described in the following section. 
4.3  CASE STUDY SET UP 
4.3.1  New product development process 
In this study, we used the previously established new product development 
process in biopharmaceutical industry. This process was also adopted in the 
analysis of benchmarking the cost of developing biopharmaceutical product 
portfolio aiming at one market success in Chapter 3. The model captured the 
process from the pre-clinical phase through to the product market launch. 
Manufacturing  and  process  development  activities  supporting  the  pre-
clinical and clinical trials were planned at risk so that no delays were caused 
in  the  critical  path  of  clinical  development.  The  dependencies  of  these 
activities were shown in Figure 3.1. Every square represents an activity that 
consumes budget and time of the drug developer in this model. Activities on 
the  critical  path  were  subjected  to  development  failure,  which  was 
addressed by transition probabilities in Monte Carlo simulations.  
The benchmark results for developing a single biopharmaceutical product 
presented  in  Chapter  3  were  used  as  inputs  in  this  case  study,  and  are 
summarized in Table 4.1. Chapter 4  
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Table  4.1  Durations  and  costs  for  developing  a  single  biopharmaceutical 
product.  
    PC  I  II  III  FDA  
CT   Cost ($million)  4.4  31  35  77  3 
  Duration (year)  1  1.6  2.4  2.7  1.5 
PD  Cost ($million)  1.5  0  1.5  10  27 
  Duration (year)  1  0  0.5  2  1.5 
Manu   Cost ($million)  1.11  1.27  1.27  9  0 
  Duration (week)  6  5  5  13  0 
Note: CT – clinical trial. PD – process development. Manu – manufacturing. PC – 
pre-clinical stage. I to III – Phase I to Phase III stage. FDA – FDA review stage. 
 
4.3.2  The candidate pool 
In order to illustrate the functionality of this tool, the candidates in this case 
study were designed such that no obvious solutions can be derived by using 
simple rules such as maximum expected NPV. Risk-reward trade-offs were 
specifically built in by varying the transition probabilities of products and 
their potential market values.  
The  candidates  were  identical  in  terms  of  durations  and  costs  of  the 
activities, but differed in their chances of successfully reaching the market. 
Table 4.2 presents the risk profiles for candidates from low, medium, and 
high risk groups, which were the same as the phase transition probabilities 
used in Chapter 3 for benchmarking the development cost of developing 
drug portfolio aiming at a single market success. 
Table 4.2  Candidate risk profiles.  
  PC  Phase I  Phase II  Phase III  FDA review 
Low risk  70%  85%  55%  70%  91% 
Medium risk  69%  54%  34%  70%  91% 
High risk  69%  54%  34%  21%  91% Chapter 4  
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(Continued) Note: The transition probabilities from medium risk group are from 
published  sources  on  industrial  average  pharmaceutical  development  cost  study 
(Paul et al. 2010); The low risk transition probabilities are derived from the higher 
values of published transition probabilities for each phase (DiMasi & Grabowski 
2007; Nelson et al. 2010; Bogdan & Villiger 2010); The high risk groups take on 
the transition probabilities of the medium group from pre-clinical to Phase II, but 
the  Phase  III  probability  is  lower  to  reflect  the  case  for  indications  such  as 
Alzheimer’s disease. 
 
The candidates were also designed to have the same, positive expected NPV, 
regardless of their risk profiles. In order to achieve this, their market values 
were  tuned  accordingly.  The  market  value  of  a  product  candidate  was 
defined  as  the  sum  of  all  discounted  future  cash  flows  brought  by  the 
product.  It  was  evaluated  after  all  the  costs  related  to  marketing  and 
manufacturing of the products have been accounted for, therefore in the 
model simulation the market value was realized once the candidate reaches 
the market. For the low, medium, and high-risk candidates, their respective 
market value was set to $1500 million, $5200 million, and $21000 million 
respectively.  In  practice,  the  market  value  of  a  candidate  can  be  easily 
translated into peak sales of the product once the sales curve and product 
life is determined. For instance, assuming the product peak sales occurs at 
the 11
th year of entering the market, and the product life is 21 years, $1500 
million market value can be viewed as $600 million peak sales using the 
sales curve introduced by Bogdan & Villiger (2010) at a gross margin of 
50%. 
Thirty product candidates were created from these three risk groups, with 
each  risk  profile  represented  by  10  product  candidates.  The  number  of 
selections of product candidates in each risk group reflected the preference 
of solutions in the risk-reward trade-offs.  
4.3.3  Budget constraints 
The budget constraints in this case study were addressed by setting up an 
annually updated maximum value for development spending. The value of 
the budget constraint can directly impact the selection of product candidates. Chapter 4  
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However, budget constraints that are above a certain value can operate in a 
similar fashion to unlimited cash flow. Hence it was important to determine 
an  effective  range  of  budget  constraints  for  developing  this  particular 
candidate pool. This was derived based on the maximum requirement of 
funds in more than half (>50%) of situations.  
The budget limits in this case study were established based on the lower 
bound  of  the  maximum  budget  requirement  to  ensure  the  influence  of 
budget constraint on the selection of candidates. Under this lower bound of 
maximum requirement of budget, the budget constraint has impact on most 
of the portfolio management decisions. Table 4.3 describes the procedure to 
determine  the  lower  bound  of  maximum  annual  budget  using  binomial 
distributions. With the 10 products from each risk group at the pre-clinical 
stage,  the  number  of  products  reaching  each  development  stage  can  be 
derived  by  applying  the  binominal  model  with  the  phase  transition 
probabilities  of  each  stage.  The  minimum  numbers  of  products  reaching 
each stage in more than 50% of scenarios were used for determining the 
annual  cost  for  developing  products  from  each  risk  group.  Finally, 
combining the annual costs from the three distinct risk groups yielded the 
defined lower bound of annual budget requirement, which was $257 million 
during the Phase I stage. Because the binomial probabilities presented in 
Table 4.3 included a scenario in which the actual number of projects was 
higher than the target number, the upper bound of the maximum budget 
requirement can be well above $257 million. In this case study, the budget 
limits  were  therefore  set  to  be  from  $50  million  to  $300  million  with 
increments of $50 million.    Chapter 4  
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Table 4.3 Estimation of the lower bound of the maximum annual budget 
requirement for development of 30 biopharmaceutical R&D projects.  
Development stages  PC  I  II  III  FDA 
Duration (Year)  1  1.6  2.4  2.7  1.3 
Cost of clinical trials ($million)  4.4  31  35  77  0.3 
Phase transition probability                
Low risk projects  0.7  0.85  0.55  0.7  0.91 
Medium risk projects  0.69  0.54  0.34  0.7  0.91 
High risk projects  0.69  0.54  0.34  0.21  0.91 
Probability of reaching this stage                
Low risk projects  1  0.70  0.60  0.33  0.23 
Medium risk projects  1  0.69  0.37  0.13  0.09 
High risk projects  1  0.69  0.37  0.13  0.03 
Number  of  projects  reaching  this 
Phase with >50% probability from 
10 projects 
              
Low risk projects  10  7  6  3  2 
Medium risk projects  10  7  4  1  1 
High risk projects  10  7  4  1  1
a 
Binomial probability of having the 
above number of projects or more 
at these stages 
              
Low risk projects  1  0.65  0.62  0.69  0.71 
Medium risk projects  1  0.62  0.55  0.74  0.60 
High risk projects  1  0.62  0.55  0.74  0.24
a 
Cost per year ($million/year)                
Low risk projects  44  135.63  87.50  85.56  0.46 
Medium risk projects  44  135.63  58.33  28.52  0.23 
High risk projects  44  135.63  58.33  28.52  0.23 
Budget  required  per  year 
($million/year) 
132  257  118  101  0.52 
Note:  The  repeated  trials  are  constructed  based  on  10  independent  project 
candidates created for each group with distinct risk profiles. For each development 
stage, the probability of reaching that stage is calculated using phase transition 
probabilities of the previous stages. The number of project candidates reaching a 
certain stage given 10 independent trials is therefore a binomial distribution from  Chapter 4  
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(Continued)  which  the  lower  bound  of  the  annual  budget  requirement  can  be 
defined as the fund capable of supporting the number of projects in more than 50% 
of all the possible scenarios.  
a The probability of getting one or more projects to FDA review stage in high-risk 
group is lower than 50% from 10 candidates. This exception is made so that there 
is cost related to high-risk projects at this stage.  
 
In the model simulation, any lack of funds caused the activities to halt until 
budget was updated in the following year. Therefore a delay caused by a 
budget  constraint  could  last  potentially  as  long  as  one  year.  Delays  in 
development affect the final market launch of the product, and in turn affect 
the product’s profitability. Previous studies indicate that delays to market 
launch may result in loss of a competitive position (e.g. Kennedy 1997). 
Hence, for every year of delay, the model assumes that the product market 
value was reduced by 35%.  
In  practice,  the  real  budget  limits  can  be  obtained  through  the  study  of 
company  R&D  expenses  after  deducting  the  non-cash  items  such  as 
depreciation.  
4.3.4  Capacity constraint 
The  capacity  constraint  in  this  case  study  was  set  up  to  determine  the 
optimal  capacity  level,  and  to  maximise  the  utility  under  the  constraint 
through  portfolio  selection.  Because  of  the  probabilistic  nature  of 
biopharmaceutical new product development, capacity budgeting cannot be 
accurate  all  the  time.  The  mismatch—too  much  capacity  with  too  few 
products, or vice versa—will cause inefficiency and therefore damage the 
value of the portfolio.  
The upper bound of effective levels of capacity constraint was determined 
by configuring the capacity level such that in almost all (99%) cases the 
capacity requirement for commercial manufacturing could be fulfilled in-
house.  In  Figure  4.1,  the  capacity  of  commercial  manufacturing  was 
translated into the amount of portfolio market potential that can be achieved 
through in-house production. It was assumed that with every 120kg/year Chapter 4  
 
  113 
increase in production, $2000 million in market value could be realized, 
based on the selling price of monoclonal antibody products. The case study 
focused  on  capacity  constraints  from  120kg/year  (~50%  probability  of 
realizing the full portfolio market value) to 840kg/year (>99% probability of 
realizing  the  full  portfolio  market  value)  with  120kg/year  increments  in 
capacity to explore their impact on the risk-reward performances and the 
corresponding optimal portfolio selection decisions (see Figure 4.1). 
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4.3.5  Optimal configuration for population size and generations 
As discussed in Chapter 2, before implementing the non-dominated sorting 
genetic  algorithm  NSGA-II,  trial  runs  have  to  be  performed  to  find  the 
optimal  configurations  for  running  the  algorithm.  A  hypervolume-based 
approach was implemented to compare the performance of the algorithm 
under  various  running  parameters,  in  which  hypervolume  represents  the 
proximity  to  the  real  Pareto  front.  In  this  approach,  the  total  number  of 
evaluation was fixed at 5000 with the population size varying from 20 to 
100.  Consequently  the  maximum  numbers  of  generations  were  from  50 
(population size 100) to 250 (population size 20). The hypervolume of the 
Pareto front of the final generation was calculated to represent the overall 
performance  of  the  algorithm  in  the  multi-objective  space.  The  optimal 
population  size  was  80  as  it  yielded  the  highest  hypervolume  value 
compared to other configurations of population size.  
With  an  optimal  population  size  of  80,  the  algorithm  was  implemented 
without  any  resource  constraints  for  30  repeated  trials.  As  illustrated  in 
Figure 4.2, the hypervolume starts to converge after around 20 generations, 
and  fully  converged  before  50  generations.  Different  independent  trials 
yield  very  little  variations  in  terms  of  hypervolume,  and  they  tend  to 
converge with the increases of the generations. Therefore for the problem 
specified in this case study, it was sufficient to have 30 independent trials 
running  for  50  generations  to  produce  a  quality  Pareto  optimal  front 
consistently.  Chapter 4  
 
  116 
 
Figure  4.2  The  convergence  of  hypervolume  of  Pareto  front  for  30 
independent trials of genetic algorithm.  
The error bars are the standard errors from the distribution of hypervolume across 
30 trials.  
 
4.4  RESULTS: OPTIMIZATION UNDER RESOURCE CONSTRAINTS 
In  this  section,  the  stochastic  optimization  tool  was  implemented  under 
various configurations in order to showcase its functionality under possible 
industrial scenarios. The boundaries of optimal performances were explored 
in  the  presence  of  constraints  on  both  the  budget  and  manufacturing 
capacity fronts. Optimal solutions generated from evolutionary algorithms 
are  discussed  and  detailed  analyses  of  their  distinct  economical  and 
operational characteristics presented. 
4.4.1  Budget constraints 
Figure 4.3 shows the impact of budget constraints on decisions in portfolio 
composition and the resulting objective values. The resulting Pareto fronts 
demonstrate the trade-off between the conflicting objectives of reward, in Chapter 4  
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the form of the average positive NPV, and risk, in the form of p(NPV>0), as 
illustrated  by  the  negative  relationship  between  them.  As  the  budget 
constraints are relaxed, improvements can be observed in both optimization 
objectives  as  the  Pareto  front  shifts  to  the  right.  Hence  for  a  given 
p(NPV>0) value, the higher the budget limit the higher the average positive 
NPV  .  However,  the  effect  of  improvement  diminishes  quickly  as  the 
budget limit gets closer to the lower bound of the maximum annual budget 
requirement.  
Solutions  under  the  more  relaxed  budget  constraints  perform  better  than 
solutions  under  the  more  tight  budget  constraints  in  the  high  p(NPV>0) 
value region. Since the average positive NPV value only takes into account 
the NPVs that are positive, the higher the p(NPV>0) value, the more reliable 
the average positive NPV value. Hence the profitability of a solution can be 
compared to another only when they have a similar p(NPV>0) value. In the 
region where p(NPV>0) is greater than 0.5, solutions at the $300 million 
budget constraint dominate the solutions of all other Pareto fronts.  
From a decision-maker’s point of view, the same level of safety can be 
achieved  from  different  budget  setups  by  constructing  the  portfolio  that 
matches the budget. As described in Figure 4.3, to achieve a p(NPV>0) 
value  of  0.69  the  company  should  focus  on  low  risk  projects  when  the 
budget is at $150 million. When the budget rises, it is more profitable with 
the same level of safety to shift the focus to more medium and high-risk 
projects.  
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Further investigation into the cash flow distributions from optimal solutions 
unveiled more details of portfolio development. Figure 4.4 illustrates that 
for solutions with a 0.79 p(NPV>0) value, the maximum average annual 
out-of-pocket cost is just right under the budget level for the scenarios at the 
$150M, $200M, $250M, and $300M annual budget levels,. The years with 
the most spending on the development timeline are the 3
rd, 4
th, and the 6
th 
year, with the 6
th year being the year of maximum annual spending for a 
solution that relies most heavily on low risk projects (5L, 1M, 1H), and the 
3
rd year for solutions that lean towards medium and high risk projects.  
Costs originated from process development, manufacturing, and pre-clinical 
& clinical trials are colour-coded in Figure 4.4. Pre-clinical & clinical trials 
are the most cost-consuming in portfolio development. The costs of process 
development are mainly incurred in the 1
st & 2
nd year, the 4
th to the 6
th year, 
and  the  9
th  &  10
th  year,  which  are  often  followed  by  a  short  period  of 
manufacturing.  
The out-of-pocket costs of non-clinical activities are summarized in Figure 
4.4, in which comparisons of costs distributed to process development and 
manufacturing  activities  are  made  among  the  optimal  solutions  with  the 
same p(NPV>0) value. Phase III process development cost tops the non-
clinical costs of in portfolio development under budget constraints, followed 
by the manufacturing cost for late stage development supply. The number of 
products at different development stages is the key driver of non-clinical 
costs. At FDA review stage, the cost of process development for the optimal 
solution  under  $150  million  budget  is  higher  than  the  one  under  $200 
million budget, since the former has a slightly higher average number of 
products reaching the stage. 
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To  better  understand  the  mechanism  and  effect  of  the  annual  budget 
constraint, the optimal solution from the $300 million constraint with a 0.79 
p(NPV>0)  value  was  singled  out  as  a  performance  checker.  Simulation 
results of the cash flow performance of this solution under other budget 
constraints  are  presented  in  Figure  4.6,  with  the  costs  from  different 
development stages colour-coded. Varying from $100 to $300 million, the 
annual budget constraints have a significant impact on the average portfolio 
marketing  time.  With  an  annual  budget  constraint  of  $100  million,  it  is 
unlikely  that  the  portfolio  products  would  reach  the  market  within  the 
modelling time horizon of 14 years. When the limit changes from $200 
million to $300 million, the average time to market shortens from 13 years 
to 12 years, with the average finishing time of Phase I decreasing from the 
5
th year to the 4
th year and Phase II from 9
th year to 7
th year. The time saved 
by increasing the annual budgetary limit from $300 million to $400 million 
is negligible, as in both cases the portfolio products reach the market at the 
same  year,  although  in  the  $400  million  scenario  the  Phase  II  activities 
finished slightly earlier than in $300 million scenario. Therefore in this case 
the ideal budget level is $300 million, as increasing the budget beyond this 
value has little impact on the portfolio profitability. Lowering the budget 
level does provide smoother spending curve, but at the expense of delaying 
the time to market and hence the timing for revenue.  
Budget planning that is more flexible than a fixed annual cap can be derived 
from  this  analysis.  From  year  0  to  3,  there  is  a  sharp  increase  in  the 
requirement  of  funds  that  should  be  accounted  for  to  safeguard  the 
development  process.  Pre-clinical  and  Phase  I  costs  are  the  main  cost 
drivers during this time period. From the 4
th year to the 6
th year, while the 
total requirement of funds stays at a similar level, its distribution shifts to 
Phase II and III development stages. From the 7
th year, a lower level of 
funds  is  required  to  focus  on  Phase  III  clinical  trials  and  the  process 
development  activities  in  preparation  of  commercial  production,  till  the 
years 11 and 12 when the product finally enters the market.    Chapter 4  
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4.4.2  Capacity constraint 
This  analysis  explored  the  impact  of  clinical  and  commercial  capacity 
constraints  on  solution  performances  and  portfolio  selection  decision-
making.  Drug  developers  are  often  faced  with  the  decisions  of  future 
manufacturing capacity while there exists the possibility of product failure 
in clinical trials. The setup can also solve the optimal capacity configuration 
at a given level of safety. 
For  pre-clinical,  Phase  I,  and  Phase  II  stages,  decisions  concerning  the 
manufacturing capacity has little impact on the capacity of manufacturing 
for commercial purpose. Therefore the main reason for ensuring sufficient 
facilities to carry out the production plan is to prevent delays in the critical 
path of portfolio development. Lack of early stage manufacturing facilities 
in portfolio development may cause multiple projects queuing for the same 
facility. Simulations with full portfolio candidate products were performed 
to test the optimal setup of early stage manufacturing capacities. In Figures 
4.7 and 4.8, the impacts of changing the capacity available for pre-clinical 
and for Phase I & II production are displayed in terms of shifts in the out-of-
pocket  costs  on  the  development  timeline.  By  changing  the  capacity 
dedicated  to  pre-clinical  manufacturing  from  one  to  two  facilities,  the 
finishing times of all pre-clinical and clinical stage development activities 
are advanced by 1 year, and more importantly the final time to market of 
successful products is advanced by 1 year as well. Increasing the capacity 
from 2 to 4 facilities shows no improvement in terms of the products’ year 
of market entry. Nevertheless, using 3 facilities instead of 2 for pre-clinical 
production does shorten the length of pre-clinical stage and possibly enables 
the IND submission to occur 1 year ahead (Figure 4.7). Hence the optimal 
setup  of  pre-clinical  manufacturing  capacity  should  be  between  2  and  3 
facilities. 
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Phase I & II manufacturing tasks takes longer (10 weeks) per investigational 
product than pre-clinical manufacturing (6 weeks). The improvements of 
finishing times due to the transition from one to two facilities are 2 years 
(7
th year to 5
th year) and 1 year (9
th year to 8
th year) ahead for Phase I and 
Phase II, respectively (Figure 4.8). Increasing capacity from 2 facilities does 
not lead to significant improvement on the timing of major development 
milestones, nor does it advance the products’ market entry. Therefore the 
optimal  setup  of  capacity  for  Phase  I  &  II  manufacturing  should  be  2 
facilities. 
For Phase III and commercial production, the capacity decision not only 
determines the timing of clinical trials, but also the profitability of products 
once they enter the market. Lack of production for commercial purposes 
may force the drug developers to seek external capacity, which in this case 
study scenario, is more expensive than in-house production. On the other 
hand, building a facility for Phase III and commercial scale production is a 
major investment that will potentially cost the drug developers hundreds of 
millions of dollars. The trade-off between building in-house facility versus 
seeking outside capacity exists, especially when the required target amount 
of  production  is  uncertain.  Simulations  of  portfolio  development  under 
uncertainty were implemented to uncover the risk-reward characteristics of 
solutions under various capacity scenarios. An evolutionary algorithm was 
applied to the solution pool in order to explore the optimal combination of 
products  for  a  given  capacity  constraint.  For  each  capacity  setup,  the 
optimal solutions are displayed in the form of a Pareto front.  
Figure 4.9 highlights that from 120kg/year to 360kg/year, the performance 
of Pareto fronts improves significantly. However, the rate of improvement 
diminishes rapidly above the 360kg/year level (83% coverage of the all-
candidate  portfolio  market  potential).  Therefore,  aiming  at  around  80% 
coverage  of  all  candidate  projects  can  be  used  as  a  simple  rule  when 
encountered with capacity planning decisions.  
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From 120kg/year to 360kg/year, the selection towards projects from distinct 
risk-reward groups drives the shift from high-risk, high-reward region to 
low-risk, low-reward region. Figure 4.10 depicts the Pareto optimal fronts 
of 120kg/year, 240kg/year, and 360kg/year constraints from the selection 
point  of  view.  Overall,  the  increase  in  p(NPV>0)  is  determined  by  the 
increase in total number of projects selected, and projects with medium-risk, 
medium-rewards turn out to be the backbone behind the transition in all 3 
scenarios. The selection of low-risk, low-reward projects remains low for 
the  120kg/year  constraint,  but  increases  in  number  when  p(NPV>0) 
increases under the constraints of 240kg/year and 360kg/year. For the high-
risk,  high-reward  projects,  they  are  less  likely  to  be  selected  in  the 
120kg/year scenario when p(NPV>0) increases. The frequency of selection 
of  these  projects  remains  constant  in  the  240kg/year  and  360kg/year 
scenarios. 
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Moving from 480kg/year to 840kg/year, the capacity constraint begins to 
lose  its  impact  on  the  performance  of  the  drug  development  portfolio. 
Solutions  from  Pareto  fronts  were  aggregated  based  on  their  p(NPV>0) 
values  into  3  categories:  0.2~0.4  (high-risk),  0.4~0.6  (medium-risk),  and 
0.6~0.8 (low-risk). Unpaired t-tests were performed on the solutions from 
the  same  risk  category  to  confirm  the  impact  of  capacity  constraints  on 
average positive NPV. As shown in Table 4.4, in the medium-risk region, 
there is no significant difference of average positive NPV except when the 
capacity increases from 600kg/year to 720kg/year. In the low-risk region, 
the only significant difference exists between the capacities of 480kg/year 
and  600kg/year.  The  non-significant  differences  in  risk-reward 
performances under these capacity constraints can be attributed to the cost 
of acquiring the capacity units ($88 million per unit). Therefore, the benefit 
of  increasing  annual  production  capacity  drops  significantly  after  the 
360kg/year capacity level, hence the paramount need for having at least 
360kg/year  production  capacity  under  the  current  configuration  of  the 
candidate pool. 
Table 4.4 P-values between average positive NPVs of solutions from various 
capacity constraints separated by their p(NPV>0) performances.  
Medium risk region  480kg/year  600kg/year  720kg/year 
600kg/year  0.2104 
   
720kg/year  0.0001633  0.009213 
 
840kg/year  0.0001058  0.005385  0.7344 
Low risk region  480kg/year  600kg/year  720kg/year 
600kg/year  0.01282 
   
720kg/year  0.02918  0.8204 
 
840kg/year  0.5645  0.3096  0.3977 
Pareto optimal fronts of scenarios with capacity constraints from 480kg/year to 
840kg/year  were  divided  based  on  their  p(NPV>0)  into  low-risk  (0.2~0.4), 
medium-risk  (0.4~0.6),  and  high-risk  (0.6~0.8)  regions.  The  average  positive 
NPVs  of  solutions  from  the  same  region  were  tested  for  impact  of  changing 
capacity  using unpaired 2-tailed  student  t-test.  Significant  results  from  a  single 
incremental of capacity constraint are highlighted. Chapter 4  
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4.5  RESULTS: CANDIDATES WITH VARIOUS STARTING STAGES 
In the case study presented in this subsection, a more realistic scenario of 
product candidates is designed so that not every product starts at the pre-
clinical  stage.  For  the  products  with  higher  risk,  they  are  also  more 
advanced in the development pathway. Table 4.5 depicts the changes made 
to the candidate pool, including the addition of upfront costs for the more 
advanced products.  
Table  4.5  Starting  stage,  risk  profile,  market  value,  and  upfront  costs  for 
candidates from a more realistic scenario.  
Risk 
profile 
Starting 
stage 
% to 
market 
Post-launch NPV 
($million) 
Upfront cost 
($million) 
Low  Pre-clinical  21  1500  0 
Medium  Phase II  21  5200  25 
High  Phase III  19  21000  35 
The risk profiles and market values of candidates are the same with the previous 
study. In this study, it is assumed that all low risk candidates are in-house without 
any upfront cost to develop. The upfront costs of the more advanced candidates 
from medium and high risk groups are from Anon. (2013). 
 
To effectively limit the decisions towards the product candidates, budget 
constraints specifically focused on upfront purchases were introduced. The 
drug developers cannot make an upfront purchase of candidates worth more 
than  $105,  $350,  and  $600  million,  which  is  equivalent  to  3  high  risk 
products, 10 high risk products, and all the medium and high risk products 
(unlimited), respectively.  
The introduction of upfront budget limits has impact on the performances of 
best solutions. From Figure 4.11, the reward changes significantly when 
raising the limit from $105 million to $350 million or remove the limit. 
However, the improvement from $350 million to unlimited upfront budget 
is not as significant as the one from $105 million to $350 million. Chapter 4  
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The limitation of $105 million upfront budget prevents the Pareto front from 
exploring the high p(NPV>0) region by massively in-licensing high market 
value Phase III products. With $350 million and an unlimited budget for 
upfront purchase, the Pareto fronts stay in the p(NPV>0) >0.8 region. 
   Chapter 4  
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The distribution of NPVs of solutions from Pareto optimal fronts unveils the 
possible  outcomes  of  portfolio  development.  With  limited  budget  for 
purchasing  late-stage  projects,  the  distribution  of  NPVs  is  largely 
determined by the success of a few key products, showing a disconnected 
distribution of NPVs. With the addition of the more reliable medium and 
late-stage  projects,  the  distribution  of  NPVs  becomes  more  continuous, 
reflecting a more steady performance.  
Selections from Pareto optimal fronts of various upfront budget constraints 
reflect the function of product candidates from distinct groups. Under the 
$105 million limit, the low-risk, early stage, upfront free products drives the 
increases  of  p(NPV>0).  With  higher  budgets  for  upfront  payment,  the 
algorithm selects solutions that take advantage of the late stage, high market 
value products.  
A trade-off between the products starting from Phase II and the ones starting 
from Phase III exists in $105 million budget Pareto front in the transition 
from  high-reward,  high-risk  region  to  low-reward,  low-risk  region.  With 
unlimited budget for purchase, the Pareto front converges into picking all 
the high market value Phase III products. 
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Based  on  this  analysis,  the  decision-maker  can  adjust  the  portfolio  risk-
reward preference by switching products from different groups when under 
constraint. However, the optimization results are contingent on the accuracy 
of model inputs, which can be difficult to achieve. By using the evaluation 
engine on optimal solution alone, the effect of inaccurate or uncertain inputs 
can be measured.  
Additionally, the acceptable upfront costs when in-licensing projects under 
portfolio perspective can be explored. From the same starting point of 9 
early stage, low-risk projects, 4 Phase II, medium-risk projects, and 0 Phase 
III, high-risk projects, the tool evaluates the results of performance change 
when 1 Phase III project is in-licensed. Figure 4.13 shows the possibility of 
having  inefficient  transition  through  the  in-licensing  deal  or  gaining 
absolute value based on different upfront costs. When the upfront cost is 
under  $152  million,  the  in-licensing  deal  improves  the  portfolio 
performance  in  terms  of  both  the  p(NPV>0)  and  the  expected  NPV. 
Between $228 million and $1153 million, the deal results in mutually non-
dominated  performance  with  the  original  state,  sacrificing  p(NPV>0)  in 
exchange of expected NPV. When the upfront cost is $1730 million or more, 
which represents the expected NPV of this single project, the deal turns out 
to be inefficient as it results in a reduction in both aspects of performance. 
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4.6  CONCLUSION 
The  stochastic  optimization  tool  for  biopharmaceutical  portfolio 
management decision-making proposed in Chapter 2 was implemented this 
chapter. Case studies focusing on portfolio management decision-making 
and  its  interactions  with  budget  and  capacity  resource  constraints  were 
formulated  and  the  results  discussed.  The  setup  of  biopharmaceutical 
product candidate pool took shape from the cost benchmarks produced in 
Chapter  3,  and  the  combinations  of  products  from  distinct  risk-reward 
characteristics were discussed based on the results of optimization under 
constraints of various levels. The capability of the activity-based, object-
oriented drug portfolio development model was illustrated, and in particular, 
the information within the data reports regarding the cost distribution across 
development stages and activity categories was visualized. Therefore this 
stochastic optimization tool is able to assist the decision maker by offering 
the  option  to  implement  the  optimal  solutions  with  detailed  planning  of 
budget and manufacturing capacity.  
The design of the tool allows more flexibility be introduced in formulating a 
diversified  candidate  pool,  in  which  not  all  products  are  from  the  same 
starting  stage.  A  mechanism  relating  to  in-licensing  a  product  was 
integrated by factoring in the upfront costs for the more advanced products. 
Budget constraint on the maximum upfront payment was designed so that 
the selections between the more advanced, high market potential, outside 
products and the less advanced, low market potential, in-house products can 
be  in  conflict,  and  therefore  optimization  of  strategy  was  required.  The 
performances of solutions from Pareto fronts of optimization under different 
upfront budget constraints are not comparable, as the Pareto front of high 
upfront  budget  completely  dominates  the  one  of  lower  upfront  budget. 
Finally,  the  evaluation  engine  was  utilized  for  determination  of  critical 
transition  boundaries  when  in-licensing  products  from  in  portfolio 
development  context.  The  product’s  upfront  cost  is  key  to  distinguish Chapter 4  
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whether  an  in-licensing  deal  leads  to  absolute  portfolio  value  gain  or 
inefficient transaction.  
 CHAPTER 5   
DRUG DEVELOPMENT LIFECYCLE COST MODEL IN 
PRACTICE: AN APPLICATION TO CELL THERAPY 
PRODUCTS 
5.1  INTRODUCTION 
The drug development lifecycle cost model introduced in Chapter 3 is a 
general-purpose  model  for  all  pharmaceuticals  that  have  similar 
development patterns. The cell therapy industry (CTI) is a fast growing field 
that could potentially treat millions of patients and generate revenues in the 
magnitude  of  tens  of  billions  over  the  next  decade.  The  stages  in  the 
development  cycle  for  cell  therapy  products  are  similar  to  those  for 
pharmaceutical products in general, with clinical trials on the critical path 
and  non-clinical  activities  to  support  the  progression  of  clinical  trials. 
However, there are significant differences in the size of clinical trials and 
the  success  rates.  In  addition,  cell  therapy  products  require  different 
manufacturing processes to biopharmaceuticals given that living cells are 
the  final  product.  The  manufacturing  of  cell  therapy  products  follows  a 
different  process  and  hence  requires  different  cost  calculation  methods. 
Given  these  differences,  the  benchmark  cost  evaluation  in  Chapter  3 
developed for biopharmaceuticals needs novel features to be incorporated 
for  applying  to  cell  therapy  products  with  their  specific  development 
characteristics.  In  this  chapter  the  development  specifics  of  cell  therapy 
products are addressed and the drug development lifecycle cost model is 
implemented to characterize the cost of cell therapy product portfolios. The 
drug  development  costs  for  cell  therapies  are  compared  to 
biopharmaceuticals, focusing on the differences in the total cost and non-
clinical cost ratios. This chapter also extends the analysis of how delays in 
development impact the decision-making by capturing the potential revenue 
loss. Chapter 5 
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This  chapter  is  structured  as  follows.  Section  5.2  provides  a  brief 
description of the cell therapy product development lifecycle, with emphasis 
on  its  specific  phase  transition  probabilities  and  clinical  trial  size.  The 
estimation of the market potential of cell therapy products is discussed in 
Section 5.3. The cost evaluation of developing a single cell therapy product 
is presented in Section 5.4 with a comparison to biopharmaceutical products. 
In Section 5.5 an analysis of the costs for developing a portfolio is discussed 
as well as the impact of delays on potential market revenue loss.  
5.2  DEVELOPMENT OF CELL THERAPY PRODUCTS  
5.2.1  Development lifecycle description  
The development process of cell therapy products follows the same stages 
as biopharmaceutical products, as described in Chapter 3. In a nutshell, the 
clinical trials from Phase I to Phase III form the critical path of development, 
with timely scheduled non-clinical activities, i.e. manufacturing and process 
development,  providing  support  for  trial  progression  and  eventually 
commercial launch. These non-clinical activities are scheduled such that the 
clinical trials on the critical path suffer no delay, therefore minimizing the 
time to market. This inevitably leads to the fact that part of, or the entire 
non-clinical  activity  for  a  given  development  stage  takes  place  without 
knowing whether the clinical trial that it underpins will commence or not. 
With a potential possibility of failure in clinical trials, the manufacturing 
and process development activities are actually running “at-risk”.  
Apart  from  maintaining  these  important  assumptions  about  the  product 
development  cycle,  changes  have  to  be  made  when  applying  the  drug 
development lifecycle cost model to cell therapy products. Firstly, the scope 
of development stages in this study focused on Phase I to FDA review and 
preclinical trials were not included given insufficient data at this point to 
estimate the cost components with confidence. Users of this tool can easily 
change this assumption as more information becomes available.  Chapter 5 
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Secondly,  the  method  of  producing  material  for  clinical  trial  supply  is 
different  from  protein-based  biopharmaceuticals.  Therefore  a  different 
process economics model was required to capture the cost of manufacturing. 
Instead of using a product mass-based calculation, the cell therapy product 
manufacturing target is characterized by the number of cells required. In this 
study, a UCL process economics model (Simaria et al. 2014; Hassan et al. 
2014a) was used to estimate the cost of a cell therapy manufacturing process 
featuring  10-40  layer  cell  factories  (CF-10  &  CF-40)  for  cell  expansion 
followed  by  tangential  flow  filtration  (TFF)  for  volume  reduction  and 
washing and finally fill-finish. 
Finally,  data  was  collated  to  estimate  the  clinical  trial  success  rates  and 
clinical trial patient population sizes for cell therapy products that differ 
from general pharmaceuticals or biopharmaceuticals. This is discussed in 
detail in the following sections.  
5.2.2  Phase transition probabilities  
According  to  the  FDA,  “cell  therapy  products  include  cellular 
immunotherapies, and other types of both autologous and allogeneic cells 
for certain therapeutic indications”. This study focuses on allogeneic cell 
therapies  (universal  donor)  that  have  a  similar  business  model  to 
biopharmaceuticals  that  is  product-driven  rather  than  service-driven, 
provides off-the-shelf products and can benefit from scale-up. Examples of 
approved  allogeneic  cell  therapies  include  Prochymal  (Osiris)  for  GvHD 
and Cartistem (Medipost) for osteoarthritis.    
Cell therapies  are considered to be specific due to the cell types introduced 
and  do  not  directly  interfere  with  other  physiological  functions.  Small 
molecule therapies, on the other hand, are generally considered less specific. 
They  may  interfere  with  multiple  targets  simultaneously,  which  likely 
results in higher toxicity and lower efficacy. Therefore, for the purpose of 
this analysis on cell therapies, clinical trial success rates for large molecule 
therapeutics provide a more relevant scenario than those for small molecule Chapter 5 
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therapies. A recent study on pharmaceutical clinical trials shows that for 
large molecules, the phase transition probabilities for Phase I, II, III, and 
FDA review are 66%, 38%, 60% and 89% (Hay et al. 2014). Table 5.1 
summarizes  various  sources  for  biological  and  pharmaceutical  product 
phase transition probabilities. 
Table  5.1  Phase  transition  probabilities  for  biopharmaceutical  and 
pharmaceutical products 
Phases  I  II  III  FDA   PhI LOA
a  PhI N
b 
Large molecules  
(Hay et al. 2014)  
66%  38%  60%  89%  13%  7.5 
Biopharmaceutical  
(DiMasi et al. 2010) 
84%  53%  74%  96%  32%  3.2 
Pharmaceutical & 
biopharmaceutical 
(Paul et al. 2010) 
54%  34%  70%  97%  12%  8 
a. Likelihood of approval (LOA) for Phase I products.  
b. Expected number of products (N) in Phase I to achieve 1 approval. 
 
5.2.3  Number of patients in clinical trials 
Compared  to  most  pharmaceutical  and  biopharmaceuticals,  cell  therapy 
products typically have much fewer patients in the clinical trials, especially 
for Phase III. Based on a study summary of 8386 on-going US regulated 
clinical trials, it can be calculated that the average number of subjects per 
trial for Phase I, II, and III is 42, 102, and 906 respectively (Krall 2009), see 
Table 5.2.  Chapter 5 
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Table 5.2 Average number of subjects participating on-going US regulated 
clinical trials.  
   Phase I  Phase II  Phase III 
On-going US regulated clinical trials  1342  2600  1090 
Subjects (million)  0.057  0.266  0.988 
Subjects per trial  42  102  906 
The total numbers of trials and subjects for Phase I, II, and III are provided by 
Krall (2009). 
 
A  data  analysis  into  251  clinical  trial  registry  records  on  cell  therapy 
products shows that the median numbers of patients in Phase I, II, and III 
are  12,  50,  and  208,  respectively,  fewer  than  the  average  numbers  of 
patients for all US regulated clinical trials (Hassan et al 2014b). Considering 
the distribution of patient numbers is positively skewed and dispersed, it is 
more appropriate to use the median values than the average values as the 
standard cell therapy clinical trial patient numbers.  
Table 5.3 Cell therapy clinical trial patient number.  
  Phase I  Phase II  Phase III 
N  90  111  50 
Average  17  73  252 
SD  13  77  196 
Skewness  1.53  3.62  0.93 
Median  12  50  208 
Source: Hassan et al (2014b). Data compiled from US clinical trial registry. N – 
sample size. SD – standard deviation. 
 
The differences in clinical trial enrolment can affect the overall clinical trial 
cost, assuming the cost per patient remains constant for all products in a 
given stage.  Chapter 5 
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5.3  MARKET POTENTIAL OF CELL THERAPY PRODUCTS 
Sales revenue of product is the most essential way for drug development 
companies to recover their cost and realise the intrinsic value of products. 
Quantitative  justification  for  portfolio  management  decision-making 
ultimately lies in the profitability indicators such as net present value (NPV). 
For  pharmaceutical  products,  there  are  usually  large  variations  in  their 
market potential in terms of annual sales revenue, which makes it difficult 
to predict the profitability of any particular product. The determinants of 
sales revenue include therapeutic area, drug pricing, market competition, 
company’s sales force, etc. Empirical studies have been trying to discover 
the  correlations  between  these  determinants  and  sales  revenue  with  a 
significantly large sample of marketed products.  
However, the purpose for this study is to equip the drug portfolio developers 
with  a  tool  that  conceptually  incorporate  products’  market  potential  into 
their  decision-making  process.  This  tool  establishes  the  link  between 
portfolio development scheduling decision and its consequences in terms of 
expected  market  revenue  change.  Once  the  predictions  are  made  on 
products’ market potentials, the decision makers are able to quickly quantify 
the implications of scheduling decisions on future revenues.  
It  is  therefore  appropriate  for  this  study  to  set  the  market  potential  of 
product on par with some typical marketed cell therapy products in order to 
provide a more realistic analysis. Dermagraft, a fibroblast-derived dermal 
substitute  for  treating  chronic  diabetic  foot  ulcers  (DFUs),  grossed  $44 
million on its first year of approval by the FDA in 2008, netting $28 million 
gross profit for its originate company, Advanced BioHealing. The revenue 
income  from  Dermagraft  continued  to  grow  in  2009  and  2010,  with 
revenues of $85 million and $146 million, and gross profit of $65 million 
and $115 million (Mason et al. 2011).The sales plunged to $105 million in 
2011,  when  the  company  is  purchased  by  Shire  for  $750  million,  and 
rebounded  to  $153  million  in  2012  before  Dermagraft  was  sold  to 
Organogenesis  (Shire  Plc  2013).  Provenge,  an  autologous  cellular Chapter 5 
 
  147 
immunotherapy for the treatment of metastatic prostate cancer, brought $48 
million  revenue  for  its  originating  company  Dendreon  in  2010  when  it 
commenced  market  sales  in  May.  In  the  following  year  it  grossed  $213 
million  and  $325  million  the  year  after.  The  sales  revenue  fell  to  $284 
million  in  2013  (DENDREON  CORPORATION  2014).  Based  on  sales 
figures of these industry flagship products, the following assumptions on 
typical market potential are made. 
1.  First year revenue is assumed to be $50 million. This is on par with 
the first year sales of Dermagraft. Provenge’s first year sales only 
account for 7 months in market, therefore the real first year sales 
will  be  larger  than  $50  million.  With  sales  figures  conservative 
assumptions are preferred in this study therefore the smaller one is 
chosen.  
2.  Peak sales income is achieved on the 3
rd year of market entry. This is 
true  for  both  of  these  products.  After  the  3
rd  year,  the  sales  fall 
gradually.  
3.  The amount of peak sales is $150 million. This is again on par with 
Dermagraft, which is the smaller of the two selected products. 
4.  The  sales  ramp  up  curve  is  represented  by  the  annual  sales  as 
percentage of peak sales. For this study, the percentages are 33%, 
67%, 100%, and 80% from the 1
st year to the 4
th year of market entry. 
This is consistent with both products after converting Provenge’s 7 
months first year sales into effective 1-year sales assuming the sales 
are proportionate throughout the year. After the 4
th year, the sales 
drop to 50%, 10%, and 0% of peak sales in the 5
th, 6
th, and 7
th year. 
6 years of effective market operation of the product is assumed due 
to the limited length of patent protection.  
5.  The gross margin for cell therapy product is 65%, on par with the 1
st 
year figures on Dermagraft gross profit. As the sales increase, the 
gross margin will increase due to the economies of scale. 65% marks 
the  lower  limit  of  cell  therapy  product’s  gross  margin  and  is 
consistent with the conservative principle. Chapter 5 
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Table 5.4 summarizes the assumptions on market potential of typical cell 
therapy  product  in  this  study.  These  assumptions  are  made  based  on 
conservative principles, which lead to relatively modest sales figures.  
Table 5.4 Market potential of typical cell therapy product.  
Year(s) after market entry  1  2  3  4  5  6 
% of peak sales  33%  67%  100%  80%  50%  10% 
Sales revenue ($million)  50  100  150  120  75  15 
Gross profit ($million)  32  65  98  78  49  10 
The peak sales of $150 million occur on the 3rd year of market entry. The gross 
margin for all sales is 65%. 
 
The linkage between development scheduling and product market potential 
takes into account the effect of competition from either other originators or 
follow-on biologics. Study shows that in 1990-2003 period there are 30% of 
follow-on drugs filed the investigational new drug (IND) application prior 
to the first-in-class compound (DiMasi & Faden 2010). The introduction of 
follow-on competitions normally accompanies price discounts (Wertheimer 
et al. 2001). In this study, the effect of market competition is quantified in 
terms of penalties to the scheduling decisions that results in delay to market 
entry.  In  Chapter  4,  an  assumption  was  made  for  biopharmaceutical 
products that one year’s delay to market would lead to a 35% loss of market 
value, due to the potential damage to  the product’s competitive position 
(Kennedy 1997). Since cell therapy products are relatively new and their 
market potentially less competitive, a moderate assumption was made that 
for each year of delay, the peak sales of product is reduced by 25%.  
5.4  COST OF DEVELOPING A SINGLE CELL THERAPY PRODUCT 
5.4.1  Cost of process development 
In this study, the cost evaluation of process development activities inherits 
the framework proposed in Chapter 3, with all pre-clinical tasks transferred Chapter 5 
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to  Phase  I.  This  change  does  not  contradict  the  assumptions  on  process 
development functionality in the previous analysis as there are no Phase I 
process development tasks assigned. Since the starting point of this analysis 
is Phase I, it is safe to assume the cost of process development previously 
assigned to pre-clinical stage transferred to Phase I stage. Table 5.5 presents 
the result of in-house analysis of cell therapy process development cost and 
durations. The cell therapy process development activities are divided by 
function  into  4  categories:  process  optimization,  technology  transfer, 
process characterization & validation, and product stability. Compared to 
biopharmaceuticals, the process development costs of cell therapy products 
are similar for early stages (Phase I and II), but much lower for late stages 
(Phase III and FDA review).  
Table 5.5 Cost evaluation of process development activities for cell therapy 
product in clinical trials (Hassan et al. 2014b). 
 
Phase I  Phase II  Phase III  FDA 
Process optimization ($million)  0.5  0.5  1.5  0 
Technology transfer ($million)  0.5  0.5  0.5  2 
Process characterization & validation 
($million) 
0  0  0.18  1.9 
Product stability ($million)  0.05  0.02  0.01  0 
Total cost ($million)  1.05  1.02  2.19  3.9 
Duration (year)  0.5  0.5  2  1.5 
The  process  development  activities  are  divided  into  4  main  functions:  process 
optimization,  technology  transfer,  process  characterization  &  validation,  and 
product stability. 
5.4.2  Cost of manufacturing 
The typical manufacturing process for cell therapy products involves several 
key steps that are different from biopharmaceuticals. The cells/tissue must 
be acquired first for primary cell isolation into master & working cell banks. 
These cells are then expanded. Harvested cells from these cell cultures go 
through volume reduction and washing steps in order to properly formulate Chapter 5 
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the cell therapy product. Cryopreservation is typically used for allogeneic 
therapies to extend shelf-life, facilitate storage and distribution before they 
are tested for release to end-user handling. The key technologies in this 
process are cell factories (CFs) for cell expansion, followed  by tangential 
flow filtration (TFF) for volume reduction and washing. In this study, the 
facility for production for clinical trial manufacturing is fixed at CF-10 lots 
for Phase I and II and CF-40 for Phase III with TFF and vialing, with 10
8 
cells  per  dose  and  2  doses  per  patient  as  treatment.  The  cost  of 
manufacturing  was  calculated  using  a  UCL  process  economics  model 
specific for cell therapy products (Simiaria et al. 2014; Hassan et al 2014a). 
This model was configured with standard planar technologies throughout 
the development stages. The key input variable to the model was the target 
amount of cells to produce and the total cost of goods per batch was the key 
output  used  in  this  study.  The  cost  of  goods  included  direct  costs  (e.g. 
materials) and indirect costs such as the capital charge that is a yearly cost 
that takes into account the FCI, the facility’s useful life (10 years), and the 
interest  rate.  The  capital  charge  was  divided  by  each  manufacturing  lot 
commenced within 1 year. Table 5.6 depicts the flow of calculations for the 
cell therapy process economics model with the resulting manufacturing cost 
as output. The number of patients here is adapted from the median values of 
clinical  trial  enrolment  for  existing  cell  therapy  products  described  in 
Section 5.2.   Chapter 5 
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Table 5.6 Cost of manufacturing for developing cell therapy product.  
Development stage  Phase I  Phase II  Phase III 
Optimal technology setup 
10 x CF-10 & 
TFF & vialing 
20 x CF-10 & 
TFF & vialing 
8 x CF-40 & 
TFF & vialing 
Dose (cells/patient)  10
8  10
8  10
8 
Nr. of doses/patient  2  2  2 
Nr. of patients  12  50  200 
Nr. of lots per year  3  3  14 
Clinical trial duration (year)  1.5  2.5  3 
Manufacturing cost 
($million) 
1.18  2.33  3.25 
Note: The patient numbers are assumed to be similar with the median values of 
clinical trial enrolment for existing cell therapy products. 
 
5.4.3  Cost of clinical trials 
The  clinical  trial  activities  normally  contribute  most  to  the  total  cost  of 
developing investigational therapeutics. However, in the cell therapy area, 
due to the lack of systematic study on clinical trial costs, it is unknown what 
proportion it takes in the total cost of developing cell therapy products. It is 
therefore inevitable to make assumptions regarding the cost of clinical trials. 
In  this  study,  the  costs  of  clinical  trials  per  patient  are  assumed  to  be 
consistent  for  all  therapeutic  drugs  for  the  same  trial,  since  the  variable 
component  of  costs  of  clinical  trials  depends  on  the  number  of  patients 
participating the trial. The cost of hospital and patient recruitment can be 
considered constant regardless of the product.. The user of this tool can alter 
this assumption as it only serves to provide realistic input for the tool.  
This assumption provides essential link between existing clinical trial cost 
studies  and  cell  therapy  clinical  trial  costs.  In  Chapter  3  the  number  of 
patient  is  assumed  to  be  50,  200,  and  2000  for  Phase  I,  II,  and  III  for 
biopharmaceutical  products.  Section  5.2  establishes  the  fact  that  for  cell Chapter 5 
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therapy products the number of patient enrolment is much smaller. Hence it 
is safe to say the cost of clinical trials will be lower by a significant margin. 
The exact estimates of cell therapy clinical trial costs are summarized in 
Table 5.7, where published total phase costs were used to deduce the cost of 
clinical trials for pharmaceutical products (Paul et al. 2010).  The clinical 
trials costs for cell therapy products in Phase I and II are ¼ of the costs for 
pharmaceutical drugs. In Phase III, cost of clinical trial for pharmaceutical 
products is 10-fold the cost for cell therapy products. 
Table 5.7 Cost of clinical trials for cell therapy products.  
   Phase I  Phase II  Phase III 
Clinical trial cost (pharmaceutical, $million)  14  37  131 
Patient number (pharmaceutical)  50  200  2000 
Cost per patient ($ thousand)  275  186  66 
Patient number (cell therapy)  12  50  200 
Clinical trial cost (cell therapy, $million)  3  9  13 
Note: The cost per patient is assumed to be consistent regardless of the nature of 
therapeutic  drugs.  The  cost  of  clinical  trials  for  pharmaceutical  products  are 
derived from published total phase costs less the costs of non-clinical activities 
(Paul et al. 2010). 
 
5.5  PORTFOLIO  DEVELOPMENT  COST  EVALUATION  OF  CELL 
THERAPY PRODUCTS 
The  drug  development  lifecycle  cost  model  is  implemented  with  cell 
therapy  product  development  specific  configurations.  The  results  of 
portfolio development costs are presented for activities across development 
stages  and  clinical  versus  non-clinical  categories.  Comparisons  of  cost 
distributions are made between pharmaceutical, biopharmaceutical, and cell 
therapy portfolio development. A sensitivity analysis exploring the impact 
of changing Phase II transition probability is performed, showing that the 
required number of projects at Phase I and the early stage non-clinical cost Chapter 5 
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are most affected. Finally, the model investigates the portfolio valuation by 
constructing  cash  flows  from  development  stages  to  market  incomes, 
featuring the scenario analysis where 1-year delay occurs during the Phase 
III stage.  
5.5.1  Cost evaluation 
The  portfolio  development  cost  evaluation  is  achieved  through  model 
simulation of development activities from clinical trial, manufacturing, and 
process  development.  The  number  of  products  in  the  portfolio  was 
configured such that 1 market success can be achieved on average. The drug 
development lifecycle cost model simulates the development pathway of all 
these  products  by  deterministically  scheduling  relevant  activities  and 
produces  costs  distributions  across  both  development  stages  and  activity 
categories. 
Figure  5.1  depicts  the  cost  evaluation  of  cell  therapy  product  portfolio 
development targeting 1 market success. The overall cost of developing 1 
market  successful  product  on  average  is  $157  million.  Dividing  the 
development stages into early stage as Phase I and II, and late stage as 
Phase  III  and  FDA  review,  the  early  stage  development  costs  takes  up 
around 75% of the total cost. The most cost extensive stage is Phase II with 
$71 million out-of-pocket cost and 35% of which is spent on non-clinical 
activities, i.e. process development and manufacturing. The ratio of clinical 
trial costs from early stage to those from late stage is approximately 2.5:1. 
The total non-clinical is about 37% of the total portfolio development cost 
across all development stages. The ratio of early stage non-clinical cost to 
late stage non-clinical cost is 2.5:1. Phase II manufacturing cost tops the 
non-clinical costs with $17 million, followed by Phase I manufacturing cost 
of $9 million. The costs of process development remain flat at $7~8 million 
throughout  clinical  trial  stages  from  Phase  I  to  Phase  III.  These  cost 
distribution parameters can facilitate critical budget planning decisions in 
developing cell therapy products. The distributions of stage costs of each 
activity  categories  also  reflect  the  ideal  market  composition  in  those Chapter 5 
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activities,  which  can  be  useful  for  analyzing  gaps  in  existing  market 
composition and discovering opportunities.  
Compared to the cost evaluation of pharmaceutical and biopharmaceutical 
products discussed in Chapter 3, the cost of developing cell therapy product 
portfolio is considerably smaller. Figure 5.2 presents the comparison of cost 
distributions of portfolio development of pharmaceutical, biopharmaceutical, 
and  cell  therapy  products.  The  phase  transition  probabilities  of 
pharmaceutical  and  biopharmaceutical  product  development  are  adopted 
from  Paul  et  al.  (2010)  as  the  industrial  average  benchmark.  The  cell 
therapy  product  phase  transition  probabilities  are  represented  by  large 
molecule  success  rates  from  the  study  on  clinical  success  rates  of 
investigational  drugs  (Hay  et  al.  2014).  The  benchmark  costs  of 
manufacturing  for  all  product  categories  are  from  in-house  process 
economics model featuring specifically the material requirements of clinical 
trials.  By  analyzing  the  functional  tasks  and  personnel  of  process 
development  in  each  drug  development  stage,  the  benchmark  costs  of 
process  development  are  produced.  The  costs  of  clinical  trials  for 
pharmaceutical  and  biopharmaceutical  products  are  deducted  from  the 
published total phase costs (Paul et al. 2010; DiMasi & Grabowski 2007). 
For cell therapy products, the clinical trial costs are estimated assuming the 
cost per patient remains constant for a given stage of clinical trial and there 
are  no  fixed  cost  components.  The  comparison  presented  in  Figure  5.2 
shows that the portfolio development cost of biopharmaceutical products is 
the  highest  among  the  three,  primarily  because  of  the  large  amount  of 
spending  in  Phase  I  development.  Pharmaceutical  product  portfolio 
development cost is around the same value, but more focusing on Phase III 
development. For cell therapy portfolio development, the most cost spent is 
on Phase II, taking up almost half (~45%) of the total development cost.  Chapter 5 
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Figure  5.2  Cost  distribution  across  development  stages  for  developing  an 
R&D portfolio targeting 1 market success.  
The cost distributions across stages are presented for 3 different product categories: 
pharmaceutical, biopharmaceutical, and cell therapy products. The pie chart within 
this figure features the cost distribution across development stages for cell therapy 
product. These costs are out-of-pocket costs taking into account the costs for failed 
projects. The total portfolio development cost is on the top of each bar. The costs 
for  pharmaceutical  and  biopharmaceutical  portfolio  development  excludes  the 
costs spent on pre-clinical stage. 
 
The model also captures the cost distributed to manufacturing and process 
development  activities.  Figure  5.3  shows  the  manufacturing  and  process 
development cost distribution across all stages of portfolio development for 
cell therapy products as well as biopharmaceutical products. The overall 
cost  of  non-clinical  activities  is  $58  million  for  cell  therapy  product 
portfolio  and  $129  million  for  biopharmaceutical  product  portfolio  from 
Phase  I  to  FDA  review  stage.  Biopharmaceutical  product  portfolio 
development focuses more on FDA review stage process development since 
extensive  process  characterization  and  validation  tasks  are  required  to 
formulate the BLA documentation and the drug developing company also 
needs to prepare its commercial production. Cell therapy product portfolio, Chapter 5 
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on the other hand, is much less costly in late stage process development but 
more expensive in manufacturing to provide materials for Phase II clinical 
trial as there is quite a significant number for patient enrolment in Phase II. 
From  a  budget  planning  point  of  view,  the  transition  from 
biopharmaceutical product portfolio to cell therapy product portfolio implies 
big cuts in process development costs, especially for Phase III and FDA 
review stages, and relatively small cuts in manufacturing costs.  
 
Figure 5.3 Process development and manufacturing cost distributions across 
development stages for biopharmaceutical products and cell therapy products 
portfolio targeting 1 market success.  
The costs are out-of-pocket costs including the spending on failed projects. The 
total costs of process development and manufacturing for portfolio development 
are  presented  on  top  of  each  bar.  The  process  development  cost  of 
biopharmaceutical portfolio development in Phase I takes the value of pre-clinical 
cost as they perform similar functions in the analysis. 
 
A more detailed comparison between biopharmaceutical and cell therapy 
product portfolio development cost evaluation is presented in Figure 5.4. 
Evidently  it  is  more  than  3  times  more  expensive  to  development  a 
successful biopharmaceutical product than a cell therapy product because of 
1)  the  higher  attrition  for  biopharmaceutical  projects:  8.6  products  are Chapter 5 
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required at Phase I for biopharmaceuticals compared to 7.5 for cell therapy 
products; 2) the higher cost of clinical trials across all clinical stages: almost 
3.5 (Phase II) to 11 (Phase I) times higher for biopharmaceuticals than for 
cell therapy products; 3) the higher cost of non-clinical activities: more than 
2 times higher in total non-clinical cost for developing biopharmaceuticals 
than for cell therapy products as described in previous paragraphs. Despite 
the higher non-clinical costs, the ratio of non-clinical cost against the total 
cost for biopharmaceutical portfolio development is much smaller than that 
of  cell  therapy  portfolio,  almost  half  the  percentage  (19%  versus  37%), 
which suggests that the cell therapy product developer should focus more on 
non-clinical activities.  
 
Figure  5.4  Cost  comparisons  between  cell  therapy  product  portfolio  and 
biopharmaceutical product portfolio development.  
The phase transition probabilities for biopharmaceutical products are from Paul et 
al. (2010) and the total phase costs are from DiMasi & Grabowski (2007). For cell 
therapy products, large molecule clinical trial phase transition probabilities (Hay et 
al. 2014) are used and the costs of clinical trials are deducted assuming constant 
cost per patient. Number of projects required in Phase I to have 1 market success in 
average is presented, as well as the cost distribution across development stages and 
activity  categories.  Non-clinical  activities  include  process  development  and 
manufacturing. a) The process development cost for Phase I for biopharmaceutical 
products takes the value of pre-clinical process development cost as they perform 
the same function. b) The percentage of overall non-clinical costs over the portfolio 
development cost. c) For biopharmaceutical products, this percentage takes into 
account the cost spent on pre-clinical stages.  
 Chapter 5 
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5.5.2  Sensitivity analysis 
Assumptions have been made in the previous analysis of cost evaluation of 
cell therapy product development since when this study carried out the area 
was largely unexplored. It is therefore reasonable to test the sensitivities of 
cost evaluation results against those assumptions in order to obtain a more 
comprehensive understanding of the implications should those assumptions 
fail to represent the reality. In this study, the drug development lifecycle 
cost model is implemented with changing inputs in a one-factor-at-a-time 
(OFAT)  fashion,  capturing  the  percentage  deviations  of  cell  therapy 
portfolio development cost evaluation results.  
As the stage that divides early stage and late stage and with the highest 
likelihood of project failure, Phase II is selected as the research focus in this 
study. A published research study on success rates of investigational drugs 
(Hay  et  al.  2014)  shows  that  variations  exist  in  Phase  II  transition 
probability  for  development  of  drugs  in  different  therapeutic  areas.  The 
range of possible Phase II transition probabilities is from 26% (32% lower 
than the benchmark input) to 50% (32% higher than the base case input).  
Figure 5.5 presents a sensitivity analysis of the portfolio cost determined by 
the model to the Phase II transition probability as well as other key model 
variables. In general, the increases in percentage variations of costs from 
base case are larger than the decreases caused, if changing the Phase II 
transition probability at the same magnitude. Similar percentage variations 
appear for projects required at Phase I, the early stage non-clinical cost, and 
the  Phase  II  stage  cost,  revealing  the  fact  that  the  calculation  of  these 
parameters follows the same principle of calculating expected values. The 
model constructs a portfolio based on attrition rates in order to get 1 market 
success, and works on the cost of activities from each stage by multiplying 
the cost of that activity with the number of projects required in that stage.  
The variations of total clinical trial cost as well as total cost of portfolio 
development are smaller than the variation of Phase II stage cost, since there 
is  no  change  in  the  cost  after  Phase  II,  which  is  part  of  total  portfolio Chapter 5 
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development cost. However, there is variation for Phase III non-clinical cost 
as  well  as  its  percentage  of  total  phase  cost  because  the  non-clinical 
activities for Phase III actually starts at Phase II stage before the knowledge 
of Phase II success. Decreasing Phase II transition probability also increases 
the percentage of early stage cost against total cost, as more projects are 
required in early stages.  
 
Figure  5.5  Sensitivity analysis on cell therapy cost evaluation results when 
Phase II transition probability changes.  
The Phase II transition probability varies from 38% in benchmark analysis to 26% 
as  the  lowest  possible  value  and  50%  as  the  highest  possible  value  for  all 
therapeutic areas. The variations of cost evaluation results are reflected in terms of 
percentage increases or decreases from the benchmark.  
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5.5.3  Portfolio valuation and impact of delay to market 
The drug development lifecycle cost model is capable of capturing portfolio 
development timelines and milestones, therefore constructing expected cash 
flows. With the projections of a product’s market revenue and profit margin, 
the  portfolio  NPV  can  be  achieved  by  the  discounted  cash  flow  (DCF) 
method that combines the cash flow generated from cost of development 
and profit of marketing the product.  
Considering the cost of portfolio development as cash outflow or negative 
cash flow, and the profit from market revenue as cash inflow or positive 
cash flow, the cash flow chart of developing a cell therapy product portfolio 
targeting one market success is established in Figure 5.6. For the first 5 
years of development, the annual cost of portfolio development is around 
$20 million except for the 3
rd year where the cost surges to more than $40 
million, which deserves special attention from cell therapy developers as the 
increased  amount  of  cost  could  potentially  cause  delay  because  of  the 
shortage of development budget. Once after the product’s market entry, the 
drug developer should expect an injection of profit that almost covers all 
portfolio development cost. Measures should be taken at this point to ensure 
the  level  of  market  penetration  that  strengthens  the  sales,  and  to  seek 
opportunities for making good use of the increased capital.  Chapter 5 
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Figure 5.6 Expected cash flows for developing cell therapy product portfolio 
targeting 1 market success.  
The cost evaluation figures are separated by the time of cost incurring. All cost 
figures are treated as negative cash flow to the drug development company, with 
all gross profits from marketing the product contributing to positive cash flow. 
Scenario where 1-year delay occurs in Phase III development stage is analysed and 
the results presented along with benchmark results. The revenue and gross profit 
loss  due  to  the  increased  likelihood  of  competition  after  delay  are  captured. 
Portfolio NPVs are produced for both scenarios based on a 10% discount factor 
specific for pharmaceutical industry NPV calculations.  
 
The simulation presented in Figure 5.6 also captures the effect of a 1-year 
delay in Phase III development. It not only causes the market entry to delay 
accordingly,  but  also  decreases  the  peak  sales  by  75%  because  of  the 
increased amount of competition introduced by the delay. With the limited 
time of patent protection, the total market operation time of the product is 
also reduced, resulting the revenue loss of ~$300 million or profit loss of 
~$135 million. From a portfolio NPV perspective, the original development 
scheduling provides $2 million in negative expected NPV when applying 
10% discount rate, which is reasonable considering in this study the more 
conservative assumptions of product market potential are employed. With 
the 1-year delay scenario, the portfolio expected NPV drops to negative $47 
million, which will not be tolerable to most decision makers.  Chapter 5 
 
  163 
5.6  CONCLUSION 
In this chapter, the drug development lifecycle cost model was implemented 
to benchmark the cost of developing cell therapy product portfolio aiming at 
1 market success. The costs of clinical trials, manufacturing, and process 
development across the development lifecycle of cell therapy product were 
estimated  in  a  single  product  basis  as  inputs  to  the  model.  The  cost 
evaluation of portfolio development resulted in a total out-of-pocket cost of 
$157 million per successful cell therapy product. Results of pharmaceutical 
and  biopharmaceutical  portfolio  development  cost  evaluations  were 
compared with cell therapy products, emphasizing the cost features of non-
clinical activities and their proportions to the total portfolio development 
cost. A sensitivity analysis investigating the impact of changing Phase II 
transition probability on the evaluation results was presented, revealing key 
mechanisms of the cost evaluation process and the magnitude of possible 
variations. Finally, an analysis utilising the cash flow functionality of the 
model  explored  the  valuation  capability  of  this  tool  by  introducing  the 
product’s potential market revenue and captured the ramifications of delay 
from an NPV prospective.  
 CHAPTER 6   
CONCLUSIONS AND FUTURE DIRECTIONS  
6.1  INTRODUCTION 
Declining  productivity,  increasing  cost,  and  high  risk  of  failure  in 
pharmaceutical  R&D  activities  create  the  need  for  effective  portfolio 
management  decision-making  and  implementation.  Finding  the  optimal 
portfolio composition from the myriad combinations of available product 
candidates is further complicated by the constraints in both R&D budget 
and manufacturing capacity. Portfolio composition decisions separated from 
the  explicit  characterisation  of  the  cost  distributions  are  of  little  use  to 
portfolio managers, as inadequate budget planning can cause delays that are 
detrimental  to  portfolio  value  realization.  This  chapter  summarizes  the 
efforts made in this thesis in developing computational decision tools that 
produce  quality  portfolio  management  solutions  while  providing  critical 
cost  evaluations  for  budget  planning  purpose.  Future  developments  that 
advance the understanding of these subjects are also discussed.  
6.2  OVERALL CONCLUSIONS 
The main focus of this thesis has been the design and implementation of 
computational  decision  tools  that  perform  fast  cost  evaluation  of  drug 
development process and facilitate biopharmaceutical portfolio management 
decision-making  under  uncertainty  and  with  resource  constraints.  To 
achieve this, an activity-based, object-oriented drug development lifecycle 
cost  model  was  proposed  to  represent  the  biopharmaceutical  portfolio 
development activities of both clinical and non-clinical aspects. This tool 
was implemented in Chapter 3 to benchmark the cost of developing and 
manufacturing therapeutic biologics across the drug development lifecycle. 
The  costs,  durations,  risks  and  interdependencies  of  clinical  trial, 
manufacturing,  and  process  development  activities  were  captured  on  a 
single  product  and  portfolio  development  basis.  Three  representative 
clinical  risk  profiles  and  two  industrially  relevant  average  stage  cost Chapter 6 
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alternatives  were  utilised  in  formulating  case  studies  that  lead  to  the 
analyses  of  clinical  and  non-clinical  costs  required  at  each  phase  of 
development to ensure a market success each year. The costs of process 
development and manufacturing activities at each stage and their proportion 
of the total cost were also investigated under these risk profiles and cost 
scenarios. Link between the efforts that minimize the risk of delay and their 
economic  implications  in  cost  evaluation  was  established  through  a 
probabilistic approach that applied uncertainties to the durations of activities.  
The  drug  development  lifecycle  cost  model  was  also  implemented  to 
benchmark the cost of developing cell therapy product portfolio aiming at 
one  market  success.  In  Chapter  5,  the  differences  between  cell  therapy 
product and biopharmaceutical drugs in manufacturing process and clinical 
trial size were discussed and the out-of-pocket cost for developing a single 
cell  therapy  product  was  estimated.  The  cost  evaluations  of  portfolio 
development for biopharmaceuticals and for cell therapy products aiming at 
one market success were compared, highlighting the cost characteristics that 
involve non-clinical activities and their propositions to the total portfolio 
development cost. The possibility of inaccurate estimate of clinical success 
rates was addressed by exploring the impact of changing Phase II transition 
probability  on  the  evaluation  results.  The  analysis  of  delay  was  further 
extended in this chapter by capturing its potential damage to portfolio NPV. 
The biopharmaceutical portfolio management stochastic optimization tool 
was designed based on the drug development cost model that functions as 
the evaluation engine with Monte Carlo simulation techniques to capture the 
drug  development  uncertainties  and  dynamic  simulation  mechanisms  to 
resolve resource allocation. Performance assessments to biopharmaceutical 
portfolio management solutions were produced by this evaluation engine in 
the form of NPV distributions. A binary string representation of portfolio 
management  decisions  was  introduced  for  its  flexibility,  efficiency,  and 
simplicity. The two key statistics of NPV distributions, the average positive 
NPV  and  the  probability  of  NPV  being  positive,  were  utilised  as  the Chapter 6 
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measurements  of  portfolio  profitability  and  risk.  A  multi-objective 
evolutionary algorithm was implemented to efficiently search the decision 
space for optimal solutions. Data management system that produces data 
reports of various formats was designed to capture the performance of the 
optimal solutions as well as details in simulation at activity level.  
This  tool  was  implemented  in  Chapter  4  for  optimization  of 
biopharmaceutical portfolio management decision-making under effective 
budget and capacity constraints. A hypothetical product candidate pool was 
formulated  with  products  of  distinct  risk-reward  characteristics.  This 
candidate pool was further diversified in a case study by varying the starting 
stage for R&D and factoring in upfront payment. The tool was applied to 
both  scenarios,  and  the  sets  of  optimal  solutions  as  well  as  their  cost 
distributions  across  development  timeline  and  activity  categories  were 
discussed. The impacts of changing budget and capacity constraints were 
investigated  from  both  decision-making  and  implementation  perspective. 
Finally, the tool was utilized to explore critical transition boundaries that 
distinguish an in-licensing deal from “absolute value gain” to “inefficient 
transaction” in a portfolio context.  
In conclusion, this work contributes to the effort of providing quantitative 
support  to  portfolio  management  decision-making  in  biopharmaceutical 
industry.  The  benefit  of  combining  cost  evaluation  with  portfolio 
optimization  was  illustrated  through  the  enhanced  understanding  of  drug 
development  process,  which  would  lead  to  better  performance  in 
implementing portfolio management solutions. The tools developed in this 
thesis  is  flexible  for  adjustment  with  changing  landscape  of  industrial 
pipeline development, and can be altered to accommodate decision-makers 
with various resource attributes. Effective use of the optimization and cost 
evaluation  outcomes  can  provide  more  specific  guidance  to  drug 
development  process  from  portfolio  management  and  resource  allocation 
perspective, thus improving the financial situation of the firm and creating 
value for society.  Chapter 6 
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6.3  FUTURE WORK 
The tools developed in this thesis contribute to the effort of providing the 
portfolio management decision makers with quantitative support. Several 
improvements can be made by integrating some key techniques. 
Firstly,  more  advanced  multi-objective  evolutionary  algorithms  can  be 
applied to enhance the performance of the optimization process. Researches 
on meta-heuristics have provided algorithms that suit different problems. 
Comparisons of performances between different search algorithms can be 
made  from  efficiency  and  robustness  perspectives  to  identify  better 
solutions. A worthy alternative to NSGA-II would be the recently developed 
indicator-based evolutionary algorithm (IBEA). 
Secondly, as the risk indicator, the possibility of NPV being positive does 
not scale when the distribution of NPV has larger variations from zero. A 
tenth of a million dollar NPV cannot be reasonably regarded as “positive” 
when  the  maximum  NPV  is  a  hundred  million.  A  more  intelligent  risk 
indicator  can  be  developed  so  that  it  reflects  the  magnitude  of  NPV 
variations by re-defining what is an effective “positive”. 
Thirdly, the data generated in running of the tools can be more effectively 
managed  through  relational  databases.  The  existing  data  management 
system  designed  for  the  tools  can  benefit  from  database  normalization 
operations provided by relational database, as the data collection processes 
are  mostly  accomplished  by  multi-dimensional  arrays.  Using  relational 
databases also enables remote access to data and encourages collaboration. 
Finally,  the  simulation  model  can  be  made  more  dynamic  after  variable 
cost-of-capital is introduced. The firm’s cost-of-capital is dependent on its 
capital structure, which is in turn dependent on financing activities resulted 
from increasing R&D budget.  References 
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